

## **A Chemical Probe for Dark Kinase STK17B Derives its Potency and High Selectivity Through a Unique P-loop Conformation**

Alfredo Picado,<sup>a</sup> Apirat Chaikuad,<sup>b,c</sup> Carrow I. Wells,<sup>a</sup> Safal Shrestha,<sup>d</sup> William J. Zuercher,<sup>a</sup> Julie E. Pickett,<sup>a</sup> Frank E. Kwaracinski,<sup>e</sup> Parvathi Sinha,<sup>e</sup> Chandi S. de Silva,<sup>e</sup> Reena Zutshi,<sup>e</sup> Shubin Liu,<sup>f</sup> Natarajan Kannan,<sup>d,g</sup> Stefan Knapp,<sup>b,c,h,i</sup> David H. Drewry,<sup>a</sup> and Timothy M. Willson<sup>a\*</sup>

<sup>a</sup> Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599-7264.

<sup>b</sup> Institute of Pharmaceutical Chemistry, Max-von-Laue-Straße 9, Goethe University Frankfurt, 60438 Frankfurt, Germany.

<sup>c</sup> Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences (BMLS), Max-von-Laue-Straße 15, 60438 Frankfurt, Germany.

<sup>d</sup> Institute of Bioinformatics, University of Georgia, Athens, GA 30602, USA.

<sup>e</sup> Luceome Biotechnologies, 1665 E. 18th Street, Suite 106, Tucson, AZ 85719


<sup>f</sup> Research Computing Center, University of North Carolina, Chapel Hill, NC 27599-3420.

<sup>g</sup> Department of Biochemistry and Molecular Biology, University of Georgia, Athens, GA 30602.

<sup>h</sup> German Translational Cancer Network (DKTK) site Frankfurt/Mainz.

<sup>i</sup> Frankfurt Cancer Institute (FCI), Paul-Ehrlich-Straße 42-44, 60596 Frankfurt am Main.

## Graphical Abstract



## Abstract

STK17B is a member of the death-associated protein kinase family and has been genetically linked to the development of diverse diseases. However, the role of STK17B in normal and disease pathology is poorly defined. Here we present the discovery of thieno[3,2-*d*]pyrimidine **SGC-STK17B-1** (**11s**), a high-quality chemical probe for this understudied “dark” kinase. **11s** is an ATP-competitive inhibitor that showed remarkable selectivity over other kinases including the closely related STK17A. X-ray crystallography of **11s** and related thieno[3,2-*d*]pyrimidines bound to STK17B revealed a unique P-loop conformation characterized by a salt bridge between R41 and the carboxylic acid of the inhibitor. Molecular dynamics simulations of STK17B confirmed the flexibility of the P-loop and wide range of R41 conformations available to the apo-protein. The isomeric thieno[2,3-*d*]pyrimidine **SGC-STK17B-1N** (**19g**) was identified as a negative control compound. The >100-fold lower activity of **19g** on STK17B was attributed to the reduced basicity of its pyrimidine N1.

## Introduction

Protein kinases are a large family of enzymes that catalyze the transfer of the  $\gamma$ -phosphate from the cofactor ATP to a serine, threonine, or tyrosine residue in their substrate proteins. Structural studies show that these enzymes contain a  $\beta$ -sheet rich N-lobe and an  $\alpha$ -helix rich C-lobe that is connected by a flexible hinge into which ATP is bound.<sup>1</sup> Sequence analysis of the human genome has identified over 500 members of the kinase protein family<sup>2</sup> that have been organized into nine groups based on sequence similarity. One of these groups is the calcium/calmodulin regulated kinases (CAMK), which contains the death-associated protein kinases (DAPK) family of five serine/threonine kinases: the closely-related DAPK1–3 and the more distant STK17A and STK17B (also known as DRAK1 and DRAK2, respectively).<sup>3</sup> The five members of the DAPK family are characterized by a highly conserved N-terminal catalytic domain, but show large differences in their flanking regulatory domains. DAPK1 is a regulator of caspase-dependent and independent cell death. It is necessary for apoptosis and is annotated as a tumor suppressor whose expression is lost in many cancers. DAPK2 and DAPK3 share many of these biological functions as integrators of cell death signaling.

Much less is known about the role of STK17A and STK17B in cell signaling. STK17A expression was associated with an increase in head and neck squamous cell carcinoma through inhibition of TGF $\beta$ 1-mediated tumor suppression.<sup>4</sup> STK17A was also overexpressed in glioblastoma multiforme (GBM) and associated with decreased patient survival. Knockdown of STK17A decreased cellular proliferation, motility, and invasion in multiple GBM cell lines.<sup>4</sup> STK17B may also have a role in cancer. It is overexpressed in hepatocellular carcinoma and breast cancer, and silencing of STK17B in cells suggested that it may have utility in treatment of these malignancies.<sup>4</sup> Notably, STK17B is abundant in lymphoid organs and predominantly expressed in mature T-cells and B-cells.<sup>5</sup> STK17B knock out mice were remarkably resistant to autoimmune challenge when crossed onto a non-obese diabetic mouse strain<sup>6</sup> (a model of Type 1 diabetes) or challenged with experimental autoimmune encephalomyelitis<sup>7</sup> (a model of Multiple Sclerosis). This autoimmune protection appeared to be driven by reduction in the survival of autoreactive T-cells that were responsible for cell and tissue damage. Thus, STK17B may have a unique role within the DAPK family as an immune regulatory target.

Although STK17B may be an interesting therapeutic target in oncology and autoimmunity, there have been no selective inhibitors available to probe the sequelae of decreasing its catalytic activity in cells or animals. The only reported STK17B inhibitors are either promiscuous, show poor selectivity within the DAPK family, or lack activity in cells.<sup>4</sup> Recent efforts in broad screening have surfaced a range of scaffolds that bind to STK17B, but none with all the properties needed for a chemical probe. Among the non-selective STK17B inhibitors are quercetin **1**, which is a family-wide CAMK inhibitor,<sup>8,9</sup> and the receptor tyrosine kinase inhibitor dovitinib **2**, which has micromolar cross-reactivity with both STK17A/B<sup>10</sup> (Figure 1). Several other inhibitors have shown up to 20-fold selectivity for STK17B within the DAPK family, but none of them have been reported to be cell active.<sup>11-13</sup> Benzofuranone **3** is the only inhibitor with modest STK17B selectivity that was also reported to be active in cells. In a phenotypic assay, **3** protected islet  $\beta$ -cells from apoptosis induced by free fatty acid palmitate.<sup>14</sup>

Almost all known kinase inhibitors are heterocycles that are competitive with the cofactor ATP. The targeting of a conserved cofactor binding site can make development of highly selective kinase inhibitors a challenge. Nonetheless, medicinal chemists have been successful in exploiting some distinctive features in the ATP binding site between kinases.<sup>15, 16</sup> Approaches commonly used to gain selectivity include a) targeting a hydrophobic back pocket that is not penetrated by ATP, but which is accessible in those kinases with a small gate keeper residue (V, T, A, or G); b) exploiting the intrinsic flexibility of the hinge region between the N- and C-lobes that contains several glycine residues; c) development of covalent inhibitors that capture cysteine residues that are found in some kinases; or d) binding into an extended pocket

formed when kinases adopt an inactive conformation, called DFG-out, thus blocking ATP from access to the catalytic domain. Using one or more of these approaches, several high-quality chemical probes have been developed for protein kinases.

The kinase N-lobe contains a highly flexible phosphate-binding loop (P-loop; also referred to as the glycine-rich loop) that has received less attention for the development of selective inhibitors. The P-loop makes critical contacts with the  $\gamma$ -phosphate of ATP to support catalysis. It was observed in a kinked conformation in the structure of imatinib with ABL that supported a hydrophobic cage around the drug.<sup>17</sup> A rare P-loop conformation was seen in MAP4K4 bound to a selective inhibitor and extended analysis of crystal structures in the protein data bank (PDB) revealed an unusual conformation in 7 additional kinases.<sup>18</sup> We now report discovery of a series of potent, selective, and cell active STK17B inhibitors based on the thieno[3,2-*d*]pyrimidine PFE-PKIS 43 (**4**), which was uncovered through deep profiling of the kinase inhibitor set known as PKIS2.<sup>19</sup> Cocrystal structures of **4** and related thieno[3,2-*d*]pyrimidines with STK17B uncovered a unique P-loop flip that appears to be the molecular basis of their remarkable potency and selectivity. Optimization of the thieno[3,2-*d*]pyrimidine chemotype resulted in the first high quality chemical probe for STK17B.

## Results

*Identification of an STK17B inhibitor:* Several thieno[3,2-*d*]pyrimidines, previously published as inhibitors of Tpl2 (MAPK3K8, also known as COT),<sup>20</sup> were donated by Pfizer to the Structural Genomics Consortium (SGC) kinase chemogenomic set,<sup>19</sup> now known as KCGS.<sup>21</sup> The compounds were screened at 1  $\mu$ M through the DiscoverX *scan*MAX panel of 403 wild type human kinases and three compounds, PFE-PKIS 43 (**4**), PFE-PKIS 14 (**5**), and PFE PKIS 9 (**6**), were identified as narrow spectrum kinase inhibitors with  $S_{10}(1 \mu\text{M}) \leq 0.020$  (Table 1).<sup>19</sup> Full  $K_D$  determinations performed for all kinases inhibited >75% at 1  $\mu$ M revealed that **4–6** were potent inhibitors of STK17B with 8–60 fold selectivity over STK17A (Table 1). Notably, **4–6** were each reported to be only weak inhibitors of Tpl2.<sup>20</sup> **4** was the most potent and selective of the analogs. To probe the molecular basis of its remarkable kinase selectivity a co-crystal structure was obtained with the catalytic domain of STK17B (Figure 2). As expected, **4** occupied the ATP-binding pocket of STK17B (Figure 2A). However, the orientation of the inhibitor was markedly different to the proposed binding mode in Tpl2.<sup>20</sup> In the STK17B structure, the carboxylic acid of **4** was directed toward the catalytic lysine (K62) with the hydrophobic 6-aryl substituent extended towards the solvent (Figures 2A and B). Notably, it was the N1 of the thieno[3,2-*d*]pyrimidine that was observed to bind to the amide backbone of A113 in the hinge, not the N3 as previously proposed for Tpl2.<sup>20</sup> In addition to the interaction with K62, the carboxylic acid of **4** formed a second salt bridge with R41 of the P-loop (Figures 2A and B). The salt bridge with R41 was accommodated by a remarkable conformational change in the P-loop, in which R41 had flipped a 180° from its orientation in the structure of STK17B bound to ADP (Figure 2C).<sup>22</sup>

Although, **4** showed outstanding potency and selectivity as a potential chemical probe for STK17B, additional testing revealed that it had very low stability in liver microsomes. After 30 minutes 100% of the compound was consumed in mice liver microsomes and its  $t_{1/2}$  was determined to be < 5 min (*vide infra*). To gain insight into the low metabolic stability of **4** its P450 metabolism was modeled by SMARTCyp,<sup>23</sup> which identified the sulfur atom of the methyl thioether moiety as the most reactive part of the molecule (SI Figure 1). To improve the metabolic stability of **4** and define the structure activity for STK17B inhibition, we initiated the synthesis of a series of thienopyrimidine analogs targeting three regions of the molecule: the carboxylic acid, the heterocyclic core, and the 6-aryl group.

*Synthesis of analogs:* The synthesis 6-arylthieno[3,2-*d*]pyrimidines **4** and **11a–11ab** was adapted from the abbreviated procedures reported by Pfizer (Scheme 1).<sup>20</sup> The first step involved the deprotonation and iodination of 4-chlorothieno[3,2-*d*]pyrimidine (**7**), resulting in 4-chloro-6-iodothieno[3,2-*d*]pyrimidine (**8**) in good yield. Intermediate **8** underwent an  $S_NAr$  reaction with ethyl 2-mercaptoacetate to obtain **9**, which was saponified to **10** in good yield. Compound **10** was a key intermediate that allowed synthesis of 6-arylthieno[3,2-*d*]pyrimidines **4**, **11a–11ac** by Suzuki coupling with a range of arylboronic acids. The primary amide **12** was generated by reaction of **4** with ammonia.

Synthesis of side-chain modified analogs (Scheme 2) utilized two additional intermediates that were obtained by the regioselective Suzuki coupling of **8**, yielding 4-chloro-6-arylthieno[3,2-*d*]pyrimidines **13a** and **13b**. These intermediates were further derivatized by  $S_NAr$  reaction with ethyl 2-hydroxyacetate and ethyl glycinate, yielding esters **14** and **16**, respectively. The ester **14** was saponified to yield compound **15**.

A series of regioisomeric thieno[2,3-*d*]pyrimidines were synthesized from the commercially available 6-bromo-4-chlorothieno[2,3-*d*]pyrimidine (**17**) (Scheme 3).  $S_NAr$  reaction with 2-mercaptoacetic acid gave **18** in good yield. Thieno[2,3-*d*]pyrimidine **17** showed higher reactivity in this substitution reaction than the corresponding thieno[3,2-*d*]pyrimidine regioisomer **8**, which did not react directly with 2-mercaptoacetic acid. Suzuki coupling of **18** with several boronic acids resulted in products **19a–g** in moderate yields.

**Structure-activity relationships:** **4** and its analogs were initially screened for their STK17A and STK17B activity using a split luciferase KinaseSeeker binding assay<sup>24</sup> at a concentration of 1  $\mu$ M. Any analog showing >70% competition at STK17B was subjected to dose response to determine its IC<sub>50</sub> in the binding assay. In addition, all analogs were tested in dose response up to 10  $\mu$ M by NanoBRET assay<sup>25</sup> in HEK293 cells to determine intracellular STK17B target engagement. In the thieno[3,2-*d*]pyrimidine scaffold **A**, initial exploration focused on the  $\alpha$ -thioacetic acid side chain because of key interactions observed in the co-crystal structure of **4** with STK17B (Figure 2). In the binding assay **4** was selective for STK17B over STK17A at 1  $\mu$ M and gave an IC<sub>50</sub> of 20 nM on STK17B (Table 2), slightly weaker than the 3.8 nM K<sub>D</sub> value obtained in the DiscoverX binding assay. **4** also demonstrated robust activity in the live cell NanoBRET assay with an IC<sub>50</sub> of 310 nM (Table 2, entry 1). Substitution of -SMe for -Cl in the 6-aryl ring (**11a**) retained STK17B activity and selectivity in the binding assay (Table 2, entry 2) and showed only a small decrease in activity in cells. The primary amide analog **12** of acid **4** showed a reduced STK17B activity in the binding assay and a lack of activity in cells (Table 2, entry 3). Replacement of sulfur for oxygen in the sidechain in **15** reduced the STK17B activity in the binding assay and the analog was inactive in cells (Table 2, entry 5). Surprisingly, its ester analog **14** had equivalent (albeit low) activity in the STK17B binding assay (Table 2, entry 4), but was also inactive in cells. Double substitution of nitrogen for sulfur and ester for the acid in the side chain resulted in an analog **16** that was devoid of STK17B activity (Table 2, entry 6). The regioisomeric thieno[2,3-*d*]pyrimidine analogs **19a** and **19b** (scaffold **B**) showed only very low activity in both the STK17A and STK17B binding assays and were inactive in the cell-based assay (Table 2, entries 7 and 8). Overall, these initial results confirmed the importance of the  $\alpha$ -thioacetic acid side chain for potent STK17B activity and revealed a rather narrow structure-activity. Only **4** and its 6-chloro analog **11a** showed activity in cells, and only one regioisomer of the thienopyrimidine scaffold was active. The sensitivity of the acetic acid side chain to the nature of the  $\alpha$ -hetero substituent was surprising, since in COT/Tpl2 substitution of sulfur for oxygen was tolerated,<sup>20</sup> although with reduced activity.

Since substitution of the 6-aryl ring appeared to be tolerated in STK17B, a second round of analogs sought to explore structure activity in this part of the molecule. Analogues were synthesized in the regioisomeric thienopyrimidines **C** and **D** with the  $\alpha$ -thioacetic acid functionality in place (Table 3). Analogues in the thieno[3,2-*d*]pyrimidine scaffold **C** generally showed good STK17B binding with selectivity over STK17A (Table 3, entries 1–9). Potent activity (>70% inhibition at 1  $\mu$ M) was seen with electron-donating groups *o*-OMe, *m*-SMe, *p*-S<sup>i</sup>Pr, *p*-OBn (**11b–d**, **11j**), alkyl groups *p*-Et, *p*-vinyl, *p*-<sup>i</sup>Pr, *p*-<sup>c</sup>Pr (**11e–h**) and *m,p*-dichloro substitution (**11i**). In the cell based NanoBRET assay the most potent compounds were **11e–h** (Table 3, entries 4–7), which bear alkyl substituents in the *para* position. Surprisingly, analogs **11d** and **11j** with a *p*-S<sup>i</sup>Pr and *p*-OBn substituents were inactive in cells (Table 3, entries 3 and 9) despite having potent binding to STK17B. Compounds with substituents in *ortho* or *meta* position (**11b** and **11c**) and dichloro analog (**11i**) showed moderate activity in cells with STK17B IC<sub>50</sub> ranging from 1–3  $\mu$ M (Table 3, entries 1, 2, and 8). Most notably, **11b**, the *m*-SMe analog of **4**, was 2.5-fold less potent in the STK17B binding assay and 10-fold less potent in cells. Analogues of the regioisomeric thieno[2,3-*d*]pyrimidine **D** (Table 3, entries 10–13) again showed low activity on STK17A and STK17B, and showed no activity against STK17B in cells. This last result confirmed the initial finding in Table 2, which pointed to the lack of STK17B activity in the thieno[2,3-*d*]pyrimidine scaffold.

To explore the tolerance for polarity in the 6-aryl ring additional analogs were synthesized in the thieno[3,2-*d*]pyrimidine scaffold **C** (Table 4). In the binding assay, these compounds showed robust STK17B activity with good selectivity over STK17A regardless of the type and position of the substituent around the phenyl ring (Table 4, entries 1–7). In the cell-based assay, amides and sulfoxide (**11k–m**) were inactive (Table 4, entries 1-3). Analogues with a *p*-Ac (**11n**) and *m*-morpholine (**11o**) showed moderate activity in cells (Table 4, entries 4-5). Interestingly, compound **11p** bearing a *p*-morpholine demonstrated

sub-micromolar cell potency (Table 4, entry 6). In contrast, the acetylpyridine **11q** was inactive in cells (Table 4, entry 7).

The next series of analogs explored the reduction of electron density in the 6-aryl ring using a thiophene modification or addition of a mildly electron withdrawing group in the para position (Table 5). Two analogs where the 6-phenyl ring was replaced by thiophene (**11r**) or benzothiophene (**11s**) (Table 5, entries 1 and 2), yielded compounds with potent and selective STK17B binding and robust activity in cells. In contrast, the more electron negative *p*-CN (**11t**) and *p*-CO<sub>2</sub>Et (**11u**) derivatives were less potent in cells (Table 5, entries 3 and 4).

For the final series of analogs, the effect of fluorine substitution on the 6-aryl ring was explored with a goal to identify modifications that would be less prone to P450 oxidation (Table 6). The mono- and difluorophenyl analogs (**11v–x**) were active in the binding assay but showed only modest activity in cells (Table 6, entries 1–3). Reintroduction of the *p*-SMe substituent in **11y** resulted in a large boost in cell activity (Table 6, entry 4). In contrast, the *p*-OMe analog **11z** (Table 6, entry 5) showed a 10-fold drop in cell potency. Compounds **11aa** and **11ab** bearing a trifluoromethyl and a trifluoromethoxy substituent respectively, were found to have good binding to STK17B and sub- $\mu$ M cell potency (Table 6, entries 6–7).

In summary, the structure-activity study identified a series of 6-arylthieno[3,2-*d*]pyrimidine-4-thioacetic acids with good binding selectivity for STK17B over STK17A. Analogs with the best cell potency as measured by NanoBRET target engagement were often substituted on the 6-aryl group with small *para*-substituents, which could be either lipophilic (**4**, **11e**, **11f**, **11g**, **11h**, and **11y**) or mildly electron withdrawing (**11a**, and **11aa**). In addition, analogs with thiophene (**11r**), benzothiophene (**11s**), *p*-morpholinophenyl (**11p**), or *m*-trifluoromethoxyphenyl (**11ab**) showed good cell potency.

*Metabolic stability:* Since initial evaluation of **4** had shown it to possess poor metabolic stability, likely due to P450 metabolism of the *p*-SMe substituent, a series of the cell active 6-arylthieno[3,2-*d*]pyrimidines were selected for metabolic stability studies. In parallel, the compounds were tested for aqueous solubility and their LogD at pH 7.0 was calculated. Table 7 shows the results of this study with compounds sorted by their metabolic stability after 30 min of incubation in mouse liver microsomes. **4** (Table 7, entry 1), which showed no compound remaining after a 30 min incubation in mouse liver microsomes, had a calculated LogD in the drug-like range<sup>26</sup> and modest aqueous solubility. Replacement of *p*-SMe by *p*-CO<sub>2</sub>Et (**11u**) did not improve metabolic stability (Table 7, entry 2). Addition of a *m*-F substituent (**11y**) to the ring resulted in a small improvement in metabolic stability (Table 7, entry 3). Removal of the *p*-SMe substituent further improved metabolic stability as seen with **11c**, **11g**, **11f**, **11w**, and **11r** (Table 7, entries 4–8). **11p**, **11s**, **11h** and **11o** bearing *p*-morpholino, benzothiophene, *p*-cyclopropyl, and *m*-morpholino group, respectively, showed even greater metabolic stability, each with >50% of the compound remaining after 30 min (Table 7, entries 9–12). The fluorinated analogs **11z**, **11aa**, and **11x** showed the best metabolic stability in the series (Table 7, entries 13–15). None of the analogs showed improved aqueous solubility over **4** despite changes in their calculated LogD. The benzothiophene **11s** had lower solubility, but this did not affect its activity in cells.

*Selection of a chemical probe:* After consideration of the binding, cell potency, and metabolic stability data **11s** was selected as a potential chemical probe. Despite its lower kinetic aqueous solubility (5  $\mu$ g/mL), **11s** demonstrated the highest cell potency in the NanoBRET target engagement assay (IC<sub>50</sub> = 190 nM) among the analogs that showed <50% metabolism in the liver microsome assay. To further characterize its kinome-wide selectivity, **11s** was profiled at 1  $\mu$ M across the DiscoverX *scan*MAX panel of 403 wild type human kinase assays (SI File 1). Eight kinases including STK17B were annotated where at 1  $\mu$ M **11s** showed >75% displacement of the immobilized ligand (Table 8). K<sub>D</sub> determinations were performed by dose response for these eight kinases plus STK38L (71% I at 1  $\mu$ M) and STK17A (27% I at 1  $\mu$ M). **11s** gave a K<sub>D</sub> =

5.6 nM on STK17B in the DiscoverX binding assay, but showed some cross-activity with CAMKK2, CAMKK1, AURKB, STK17A, and PIM2. Annotations for MET, NEK6, WEE1, and STK38L were shown to be false positives in the initial *scanMAX* since they did not confirm in the dose response experiment. However, to confirm the selectivity profile of **11s** enzyme inhibition assays were performed in the presence of ATP for all 10 kinases annotated in the initial *scanMAX* experiment. In the enzyme assays **11s** showed potent inhibition of STK17B with an  $IC_{50} = 34$  nM and >100-fold selectivity over STK17A. It was also >100-fold selective over all of the other kinases tested, with only STK17A, CAMKK1, and AURKB generating a measurable dose-response ( $IC_{50}$  5–9  $\mu$ M). Robust inhibition was not seen on CAMKK2 in the enzyme assay despite its activity in the DiscoverX binding assay. As a final confirmation of the kinase selectivity of **11s**, live cell NanoBRET assays were run on STK17A, CAMKK2, AURKB, and STK38L (Table 8). **11s** showed an  $IC_{50} = 2.4$   $\mu$ M on CAMKK2 but >10  $\mu$ M on the other kinases. Thus, **11s** is a potent STK17B inhibitor with remarkable selectivity over STK17A across multiple assay formats. It had outstanding kinome-wide selectivity, with cross-reactivity on CAMKK1 and CAMKK2 as the only potential confounding activities noted in the binding assays. Importantly, **11s** is the most potent and selective cell active STK17B inhibitor reported to date and will be highly useful as a chemical probe for this dark kinase.

*Identification of a negative control analog:* To augment the utility of **11s** as a chemical probe, a close analog was designed as an inactive control (Table 9). Building on the structure activity data that showed the regioisomeric thieno[2,3-*d*]pyrimidines were inactive as STK17B inhibitors, the analog **19g** was synthesized (Scheme 3). When profiled across the DiscoverX *scanMAX* panel at 1  $\mu$ M no kinase was identified where **19g** showed >75% displacement of the immobilized ligand (SI File 1). However, **19g** did displace >65% of the immobilized ligand on 5 kinases.  $K_D$  determinations indicated that 4 of these were false positives, and only HIPK4 gave a measurable  $K_D = 290$  nM. In addition,  $K_D$  on STK17B and STK17A were measured as 0.91  $\mu$ M and 9.8  $\mu$ M, respectively. In the enzyme inhibition assay **19g** had an  $IC_{50} = 4.8$   $\mu$ M on STK17B and  $IC_{50} >10$   $\mu$ M on STK17A. **19g** was, therefore, >100-fold less active as an inhibitor of STK17B than the chemical probe **11s** (Table 9). Furthermore, in cells **19g** was inactive at 10  $\mu$ M in the STK17B NanoBRET cellular target engagement assay. Based on these activity data, and its chemical similarity to the chemical probe, **19g** is a suitable negative control for use in biological assays.

The relative inactivity of all thieno[2,3-*d*]pyrimidine analogs on STK17B was somewhat surprising. Specifically, the >100-fold decreased STK17B activity of thieno[2,3-*d*]pyrimidine **19g** compared to thieno[3,2-*d*]pyrimidine **11s** was not easily explained by a simple analysis of their shape complementarity within the ATP binding pocket of STK17B (data not shown). To further understand the molecular basis of the dramatic difference in activity between the regioisomers, density functional theory (DFT) calculations were performed to evaluate the molecular electrostatic potential as the descriptor of protonation propensity and predict the  $pK_a$  value for the respective heterocycles.<sup>27, 28</sup> A benchmark calculation was first performed on the four regioisomers of thienopyridine. The calculated  $pK_a$  values were in very close agreement with the potentiometric  $pK_a$  values reported in the literature (SI Table 1),<sup>29</sup> highlighting the dramatically lower basicity of the thieno[2,3-*b*]pyridine isomer. When applied to the thieno[3,2-*d*]pyrimidine **11s**, DFT calculated that N1 was more basic than N3 (Table 9). However, for thieno[2,3-*d*]pyrimidine **19g** both nitrogens were found to be much less basic and the relative basicity was reversed between N1 and N3. Remarkably, thieno[3,2-*d*]pyrimidine N1 of the chemical probe **11s** was calculated to be 500-fold more basic than thieno[2,3-*d*]pyrimidine N1 of the negative control **19g**. In the active thieno[3,2-*d*]pyrimidine series, N1 forms the key H-bond with the hinge motif of the ATP-binding pocket. Our computational results suggest that N1 in the negative control thieno[2,3-*d*]pyrimidine series may lack sufficient basicity to support a similar strength of molecular recognition.<sup>30</sup>

*Structural studies:* The STK17B chemical probe **11s** demonstrated remarkable kinase selectivity for an ATP-competitive inhibitor. Most notably, the amino acids lining the ATP-binding pocket of STK17A are 100%



identical except for a conservative mutation of K37 (STK17B) to R65 (STK17A) on the outside edge of the solvent accessible region. To explore whether the unusual conformation flip of the P-loop seen in the **4**/STK17B cocrystal structure (Figure 2) could contribute to kinase selectivity, the cocrystal structures of STK17B in complexes with the chemical probe **11s** and close analog **11h** were solved. The structures of **11s**/STK17B and **11h**/STK17B revealed electron density for the P-loop in two distinct conformations (Figure 3 and SI Figure 2). In conformation A, the P-loop resembled that seen in the **4**/STK17B structure, in which R41 formed a salt bridge with the carboxylic acid of the inhibitor (Figure 3B). In conformation B, the P-loop was in the orientation with R41 rotated away from the inhibitor binding pocket similar to that observed in the ADP/STK17B structure (Figure 3C). Detailed inspection of the **11s**/STK17B structure revealed only a single moderate (3.0 Å) H-bond interaction between the backbone amide of A113 in the hinge region and N1 of the thieno[3,2-*d*]pyrimidine inhibitor. In conformation A, the carboxylic acid of **11s** was held in a sandwich of salt bridges with R41 of the P-loop and the catalytic lysine (K62), and also made tight (2.5 Å) H-bonds to a water molecule and an ethylene glycol solvent molecule (Figure 3B). The 6-benzothiophene substituent sat in a hydrophobic pocket that was open to the solvent and appeared to derive most of its binding affinity through shape complementarity. The phenol of Y112 and terminal amine of K37 were the only polar residues in this region, but did not interact with **11s**. Y112 also did not appear to form a  $\pi$ -stacking interaction with the inhibitor.

The STK17B cocrystal structures of two non-selective DAPK family inhibitors, quercetin and dovitinib (Figure 3 and SI Table 2) were also solved. Quercetin is a broad spectrum inhibitor of the CAMK group,<sup>9</sup> while dovitinib inhibits the DAPK family with  $IC_{50}$  in the 1–5  $\mu$ M range.<sup>8</sup> Quercetin formed H-bonds to several STK17B residues including the hinge region, D179 of the DFG motif, and E80 of the  $\alpha$ C helix. A similar network of H-bonds was observed in the cocrystal structure of quercetin with DAPK1 (PDB 5AUW).<sup>4</sup> For dovitinib, the only polar interaction with STK17B were two H-bonds from the pyridinone to E111 and A113 of the hinge region (2.9 and 2.6 Å, respectively). Notably, in both the quercetin/STK17B (Figure 3D) and dovitinib/STK17B (Figure 3E) complexes the P-loop exhibited conformation B where neither inhibitor interacted with R41, which was rotated away from the inhibitor pocket. Thus, only in the cocrystal structures with thieno[3,2-*d*]pyrimidines-4-thioacetic acids **4**, **11s**, and **11h** was the P-loop observed in conformation A.

*Molecular dynamics:* To explore the degree to which the conformational flexibility of the STK17B P-loop could explain the remarkable potency and selectivity of **4** and **11s**, we performed molecular dynamics (MD) simulations of STK17B in the apo and inhibitor bound forms starting from R41 in both A and B conformations. Microsecond timescale simulation (1.25  $\mu$ s) of the apo-STK17B with R41 in conformation A revealed exceptional flexibility of the P-loop. Starting from conformation A, after 1  $\mu$ s, R41 switched to conformation B (Figure 4A, supplementary movie 1). This switch was characterized by an intermediate state (not observed in crystal structures) in which R41 formed a transient network of hydrogen bonds with E117, S120 and E125 in the region encompassing the helix  $\alpha$ D as well as packing against the aromatic ring of F119 (Figure 4A). In the process, the distance between E125 and R41 was reduced from 17.1 Å in the crystal structure to within H-bond distance in the intermediate state. On the other hand, 1.25  $\mu$ s long simulation of the apo-STK17B with R41 starting in conformation B did not show a switch back to conformation A. Instead R41 maintained the salt bridge with E38, as observed in the crystal structure (Figure 4B, supplementary movie 2).

In the inhibitor bound forms, both **4** and **11s** stayed bound to the protein during the 250 ns simulation time scale (Figure 5A and SI Movies 3–5). The results showed that **4** adopted two distinct conformations, due to twisting of the thienopyrimidine substituents, as shown by the increase in root mean square deviation (RMSD) at around 85 ns (Figure 5A, upper panel and SI Movie 3) while **11s** adopted only a single distinct conformation (Figure 5A, middle and lower panels and SI Movies 4 and 5). In STK17B conformation

A, the inhibitors formed more hydrogen bonds with the protein (Figure 5B, top and middle panels) than in STK17B conformation B (Figure 5B, lower panel). The higher number of hydrogen bonds can be attributed to the interaction of R41 with the inhibitors (Figure 5C, top and middle panels). In STK17B conformation B, **11s** adopted only a single inhibitor conformation in which it was bound to K62 of the catalytic pocket (SI Movie 5) despite the lack of interaction with R41 (Figure 5C, lower panel). Thus, **11s** was bound stably within the ATP-pocket independent of the interaction with R41. However, the additional salt bridge between the inhibitor and R41 in conformation A of the P-loop would be expected to increase the enthalpy of binding.

## Discussion

Despite the track record for development of kinase inhibitors as drugs for oncology, inflammation, and fibrosis, the majority of human kinases lack selective inhibitors that can be used as chemical probes to study their pharmacology.<sup>19, 31</sup> Many of these dark kinases are known to play an important role in cell signaling as shown by genetic studies.<sup>32</sup> STK17B is one such example. The phenotype of knock out mice shows that loss of STK17B protects against autoimmune challenge.<sup>5, 6, 33</sup> However, prior to our work no potent, cell active, selective STK17B inhibitor was available to study the role of this dark kinase in immune cell signaling.<sup>4</sup>

ATP-competitive kinase inhibitors generally show cross-activity with multiple kinases beyond their primary target. As a community project to create a comprehensive collection of inhibitors for every human kinase, we sought donations of molecules from pharmaceutical companies and academic investigators.<sup>19, 31</sup> The output of this project, known as the Kinase Chemogenomic Inhibitor Set (KCGS) currently contains selective inhibitors of over 200 kinases.<sup>21</sup> The identification **4** as a potent and selective inhibitor of STK17B is a powerful example of this approach. Several thieno[3,2-*d*]pyrimidines, originally synthesized as inhibitors of the kinase COT/Tpl2,<sup>20</sup> were donated by Pfizer to the project. Deep profiling of these molecules through the DiscoverX *scanMAX* panel identified activity on STK17B that was generally 100 times greater than on the original Tpl2 target.

The results of a structure-activity study showed the critical role of the  $\alpha$ -thioacetic acid for potent activity on STK17B. Replacement of the sulfur with nitrogen was not tolerated and even the switch to oxygen led to a loss in STK17B activity. In contrast, the switch of sulfur for oxygen was tolerated in COT/Tpl2.<sup>20</sup> Notably the orientation of **4** was flipped 180° compared to the proposed binding mode in Tpl2. A cocrystal structure of **4** with STK17B revealed the key role of the carboxylic acid in binding to the catalytic pocket of the kinase. The carboxylic acid was sandwiched between two residues; R41 from the P-loop and the catalytic lysine K62. Interaction with the catalytic lysine is not uncommon with polar or acidic kinase inhibitors,<sup>34, 35</sup> but the salt bridge with R41 was remarkable, given that it required a large conformational change in the P-loop. This conformational change was also seen in the cocrystal structure of the chemical probe **11s** with STK17B. Could the P-loop flip explain the remarkable selectivity of thieno[3,2-*d*]pyrimidines **4** and **11s** for STK17B over its close neighbor STK17A?

Several lines of evidence support the critical role of the P-loop in the kinase selectivity of the thieno[3,2-*d*]pyrimidines. First, the P-loop is known to be one of the most flexible regions of the kinase catalytic domain and has been implicated previously in selective inhibition of ABL and MAP4K4.<sup>17, 18, 36</sup> Likewise, molecular dynamics simulation showed that apo-STK17B can easily access both conformation A and conformation B of the P-loop. Second, quercetin and dovitinib, which bind with P-loop conformation B in their STK17B structures, show no selectivity over STK17A. The cofactor ADP also crystallized in P-loop conformation B with the position of the ribose such that it would block R41 from adopting conformation A (Figure 2c). Finally, all of the residues lining the ATP-binding pocket are identical between STK17A and STK17B making it even more likely that the remarkable selectivity of the thieno[3,2-*d*]pyrimidine inhibitors is driven by differences in conformational flexibility of the kinases. Furthermore, STK17A and STK17B differ in regions outside of the ATP binding region that might impact inhibitor specificity by altering the conformational flexibility of R41 in the P-loop, as revealed in the molecular dynamics simulation. In particular, E125 and L126 in STK17B are substituted to an aspartate (D153) and arginine (R154), respectively (SI Figure 3). These STK17A specific variations are expected to destabilize the intermediate R41 conformation observed in STK17B (Figure 4A). Thus, while the thieno[3,2-*d*]pyrimidines can access both conformations, it is only in the unique conformation A that the salt bridge with R41 would provide increased binding affinity.

The cocrystal structure of the thieno[3,2-*d*]pyrimidine-4- $\alpha$ -thioacetic acids **4**, and **11s** with STK17B showed a single 3.0 Å H-bond interaction between the pyrimidine N1 with the backbone NH of A113 in the hinge loop, which is in the range of distances typically seen for Type I kinase inhibitors.<sup>37, 38</sup> The observation of only a single H-bond suggests it is critical for molecular recognition of the thieno[3,2-*d*]pyrimidines by the STK17B hinge region. Notably, all of the regioisomeric thieno[2,3-*d*]pyrimidine-4- $\alpha$ -thioacetic acids, including the negative control **19g**, were inactive as inhibitors of STK17B almost all other kinases (SI File 1). The shape of the ATP-binding pocket in STK17B provides no insight as to why the regioisomers showed such dramatic differences in activity. A more plausible explanation for the divergent activity of the thieno[3,2-*d*]pyrimidine- and thieno[2,3-*d*]pyrimidine-4- $\alpha$ -thioacetic acids in STK17B was revealed by analysis of their electrostatic potentials. DFT calculations based on the molecular electrostatic potential of the heterocycles unveiled dramatic differences between the regioisomers as reflected by their predicted pK<sub>a</sub> values. It was already documented that related thienopyridine regioisomers showed differences in their measured pK<sub>a</sub> values; thieno[2,3-*b*]pyridine has a much lower pK<sub>a</sub> compared to the other three regioisomers due to the inductive effect of sulfur adjacent to the pyridine nitrogen.<sup>29</sup> Likewise, in the thieno[2,3-*d*]pyrimidine **19g** electron density on N1 was much lower than in thieno[3,2-*d*]pyrimidine **11s** and there was a 500-fold difference in the calculated pK<sub>a</sub>. The extremely weak basicity of N1 in the thieno[2,3-*d*]pyrimidine regioisomers may decrease their ability to be recognized by STK17B. Notably, there are some thieno[2,3-*d*]pyrimidines that have been reported as kinase inhibitors,<sup>39</sup> and in one case a thieno[2,3-*d*]pyrimidine- $\beta$ -thiopropionic acid was a potent inhibitor of CSNK2. However, it was also found that changing the salt concentration was sufficient to invert the inhibitor's binding pose such that N1 no longer interacted with the hinge.<sup>40</sup> Thus, while not all thieno[2,3-*d*]pyrimidines are devoid of kinase activity,<sup>39</sup> in the case of STK17B it appears that the more basic thieno[3,2-*d*]pyrimidine regioisomers are much more active as inhibitors.

The 6-aryl group on the thieno[3,2-*d*]pyrimidine sits in the region of the ATP-pocket that reaches towards solvent. Structure-activity studies confirmed that substitution of this ring was tolerated and could be used to optimize the cell activity and increase the metabolic stability of the series. Analogs with small lipophilic substituents on the *para*-position demonstrated some of the best cell activity, whereas the *ortho*- and *meta*-substituents were much less active. The larger thiophene and benzothiophene analogs (**11r** and **11s**) also showed potent cell activity. The most surprising result was seen with the *para*-morpholine substituent (**11p**), which had robust cell activity. In contrast, substituents that added an H-bond acceptor or donors were generally less active, as were substitutions that were electron withdrawing (e.g., -CN, -Cl, and -CO<sub>2</sub>Me). Our ability to measure STK17B target engagement in cells by NanoBRET assay<sup>25</sup> was critical in being able to navigate the subtle balance of lipophilicity and polarity required to offset the intrinsic charge of the carboxylic acid. It is notable that none of the acidic thieno[3,2-*d*]pyrimidines previously optimized as COT/Tpl2 inhibitors were reported to be active in cells.<sup>20</sup>

Modification of the 6-aryl substituent also addressed the poor metabolic stability of **4**. The *p*-SMe group was a likely site of oxidative metabolism, being predicted to be a P450 hot spot by the SMARTCyp algorithm. Replacement of the -SMe moiety with groups less prone to oxidation yielded analogs with much improved stability in liver microsomes. From the series, we selected **11s** as the analog with the best properties to be a high-quality chemical probe,<sup>41</sup> given its balance of potency, selectivity, cell activity, and metabolic stability. **11s** is a nanomolar STK17B inhibitor that has 100-fold selectivity over other DAPK family members including STK17A. It shows robust target engagement of STK17B in cells at concentrations below 1  $\mu$ M and has good stability in liver microsomes. The modest aqueous solubility does not impact its use in cell culture experiments.

Like other members of the thieno[3,2-*d*]pyrimidine series, **11s** showed outstanding selectivity across a panel of over 400 human kinases. However, two kinases that emerged as a potential off-targets were

CAMKK1 and CAMKK2. The chemical probe showed <10-fold selectivity over these kinases in the DiscoverX binding assay, although the selectivity window was greater in enzyme inhibition and cell-based NanoBRET assays (Table 8). Both the DAPK and the CAMKK families belong to the CAMK branch of the kinome. Although sequence analysis of their ATP-binding pockets predicted that cross-reactivity of Type I inhibitors would not be seen,<sup>15</sup> our recent chemocentric review highlights carboxylic acid containing compounds GSK650394 and STO6090 as potent CAMKK2 inhibitors<sup>42</sup> suggesting that there are commonalities in the ATP-binding pockets that might support the binding of acidic kinase inhibitors. Using NanoBRET target engagement assays it showed >10-fold selectivity for STK17B over CAMKK2 in cells. Thus, the cumulative binding, enzyme inhibition, and target engagement data (Table 8) indicate that at a 1  $\mu$ M concentration **11s** will be a selective STK17B inhibitor in cell-based assays.

In conclusion, **SGC-STK17B-1 (11s)** has been identified as a high-quality chemical probe for the dark kinase STK17B. The thieno[3,2-*d*]pyrimidine-4- $\alpha$ -thioacetic acid chemotype binds to STK17B with a unique conformation that sandwiches the inhibitor between the catalytic lysine and a P-loop arginine. Its remarkable kinase selectivity is likely due to interaction with the unique conformational states sampled by STK17B.

## Experimental Section

**General Chemistry.** Solvents were used as ACS or HPLC grade. Anhydrous tetrahydrofuran (THF), lithium diisopropylamide 2.0M solution (THF/heptane/ethylbenzene), commercial reagents, and catalyst were used as received. For air sensitive reactions, the glassware was oven dried and cooled under nitrogen. Low-temperature baths ( $-78\text{ }^{\circ}\text{C}$ ) were made from dry ice and 2-propanol. All the reactions were carried out under positive pressure of  $\text{N}_2$ . NMR spectra were recorded as  $\text{CDCl}_3$  and  $\text{DMSO-}d_6$  solutions on a 400, 500 or 700 MHz instrument. The  $^1\text{H}$  NMR chemical shifts are reported as  $\delta$  values in parts per million (ppm) relative to tetramethylsilane (TMS,  $\delta = 0.00$ ). The residual chloroform signal,  $\text{CHCl}_3$  ( $\delta = 7.26$ ) was used as reference and for DMSO signal (quintet, centerline  $\delta = 2.50$ ) was used as reference.  $^{13}\text{C}$  NMR chemical shifts are reported as  $\delta$  values in parts per million (ppm) relative to TMS and DMSO signal (septet, centerline  $\delta = 39.52$ ) as reference. Analytical thin layer chromatography (TLC) was performed on silica gel plates, 200  $\mu\text{m}$  with F254 indicator, visualization was accomplished by UV light (254/365 nm) or 3% ethanol solution of phosphomolybdic acid. Flash column chromatography was performed with 50  $\mu\text{m}$  irregular silica or 60  $\mu\text{m}$  spherical silica prepacked cartridges. Yields are reported as pure material after isolation by column chromatography or recrystallization. Analytical LC/MS data was obtained using a Waters Acquity Ultra performance liquid chromatography (UPLC) system equipped with a photodiode array (PDA) detector running acetonitrile/water gradient. Samples for high-resolution mass spectrometry (HRMS) were analyzed with a ThermoFisher Q Exactive HF-X mass spectrometer coupled with a Waters Acquity H-class liquid chromatograph system. Samples were introduced through a heated electrospray source (HESI) at a flow rate of 0.6 mL/min. Electrospray source conditions were set as: spray voltage 3.0 kV, sheath gas (nitrogen) 60 arb, auxiliary gas (nitrogen) 20 arb, sweep gas (nitrogen) 0 arb, nebulizer temperature  $375\text{ }^{\circ}\text{C}$ , capillary temperature  $380\text{ }^{\circ}\text{C}$ , RF funnel 45 V. The mass range was set to 150–2000 m/z. All measurements were recorded at a resolution setting of 120,000. All compounds were > 95% pure by analytical LC.

**4-Chloro-6-iodothieno[3,2-*d*]pyrimidine (8).** An oven dried 250 mL three neck round-bottom flask provided with a pressure-equalizing addition funnel, was charged with 4-chlorothieno[3,2-*d*]pyrimidine **7** (1.0 equiv, 20.0 mmol, 3.40g) was added under positive  $\text{N}_2$  pressure, followed by the addition of anhydrous THF (65 mL). Solution was cooled down to  $-78\text{ }^{\circ}\text{C}$ , LDA (2.0M, 1.2 equiv, 24.0 mmol, 12.0 mL) was added portion wise over 2–3 minutes, and the mixture was stirred for 20 min at  $-78\text{ }^{\circ}\text{C}$ . A solution of  $\text{I}_2$  (1.2 equiv, 24.0 mmol, 6.08g) in anhydrous THF (15 mL) was added over 10 min using the equalizing addition funnel. This mixture was stirred for 30 min at  $-78\text{ }^{\circ}\text{C}$ , allowed to warm up to room temperature over the course of 1 h then stirred for 2 more hours at this temperature. It was quenched with saturated  $\text{NH}_4\text{Cl}_{(\text{aq})}$ /ice water,  $\text{CHCl}_3$  added (200 mL), stirred, layers separated. The aqueous layer was extracted with  $\text{CHCl}_3$  two times, organic layers were combined and rinsed with aq.  $\text{Na}_2\text{S}_2\text{O}_8$  two times and brine two times, dried over  $\text{Na}_2\text{SO}_4$ , concentrated in vacuo, and purified over silica gel with hexanes/EtOAc in a gradient up to 100% of the polar solvent giving a clear brown solid (4.5g, 65%).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.90 (s, 1H), 7.84 (s, 1H).

**Ethyl 2-((6-iodothieno[3,2-*d*]pyrimidin-4-yl)thio)acetate (9).** In a 25 mL round bottom flask provided with a rubber septum, a magnetic stir bar, and under positive  $\text{N}_2$  pressure, 4-chloro-6-iodothieno[3,2-*d*]pyrimidine **8** (1.0 equiv, 3.5 mmol, 1.05g) was suspended in EtOH (6.0 mL) at  $0^{\circ}\text{C}$  (ice bath), followed by the dropwise addition of ethyl 2-mercaptoacetate (1.6 equiv, 5.6 mmol, 0.62 mL) and triethylamine (3.2 equiv, 11.2 mmol, 1.6 mL). The reaction mixture was stirred overnight with slow warm up from  $0^{\circ}\text{C}$  to room temperature. Dichloromethane was added to the reaction crude, solvents evaporated in vacuo, and purified over silica gel with hexanes/EtOAc in a ramp up to 15% EtOAc (the main by-product of this reaction is the des-iodopyrimidine, which elutes right after the main product). After purification, a whitish

solid was recovered (800 mg, 62%):  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.83 (s, 1H), 7.78 (s, 1H), 4.24 (q,  $J = 7.1$  Hz, 2H), 4.18 (s, 2H), 1.29 (t,  $J = 7.1$  Hz, 3H).

**2-((6-Iodothieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (10).** In a 100 mL round bottom flask provided with a reflux condenser and a magnetic stir bar, ethyl 2-((6-iodothieno[3,2-*d*]pyrimidin-4-yl)thio)acetate **9** (1.0 equiv, 2.1 mmol, 800 mg) was dissolved in a mixture of EtOH (15 mL) and THF (15 mL), followed by the addition of LiOH (2.0 equiv, 4.2 mmol, 100 mg) pre-dissolved in water (5 mL). This mixture was refluxed at 70 °C for 1h. Solvents were removed under reduced pressure and the white solid obtained was taken into ice/water and the pH adjusted to 2–3 with 2M aq. HCl. The resulting solid was filtrated, thoroughly rinsed with water, and air and vacuum dried yielding a white solid (590 mg, 80%): Melting point 183.5 – 186.0 °C.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.79 (s, 1H), 7.92 (s, 1H), 3.90 (s, 2H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  168.5, 161.4, 159.2, 154.0, 133.8, 132.3, 93.1, 33.5. HRMS (HESI) calcd for  $\text{C}_8\text{H}_6\text{N}_2\text{O}_2\text{S}_2\text{I}$   $[\text{M}+\text{H}]^+$  352.8837, found 352.8917.

**General procedure A. Synthesis of 6-arylthieno[3,2-*d*]pyrimidines (4, 11a-11ab).** In a 25 mL round bottom flask provided with a reflux condenser, a rubber septum, a magnetic stir bar, and under positive  $\text{N}_2$  pressure the following reagent were added: 6-iodothieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid **10** (1.0 equiv, 0.21 mmol, 75 mg),  $\text{K}_2\text{CO}_3$  (2.2 equiv, 0.47 mmol, 65 mg),  $\text{Pd}(\text{PPh}_3)\text{Cl}_2$  (5-6 mol%, 8-10 mg) and the corresponding arylboronic acid (1.1 equiv, 0.23 mmol). A previously  $\text{N}_2$  degassed solution of 1,4-dioxane/water (3/1, 2.5 mL) was added and the reaction mixture was stirred under mild reflux for 8-12 h. After this period, solvent was removed under reduced pressure, solids taken into ice/water, and the pH adjusted to 2-3 with 2M  $\text{HCl}_{(\text{aq})}$ . The resulting solid was filtrated, thoroughly rinsed with water, air and vacuum dried, and purified over silica gel using  $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{HOAc}$  (95/4/1) in a gradient up 5-10% of the polar solvent.

**2-((6-(4-(Methylthio)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (PFE-PKIS 43) (4).** Prepared using general procedure A, with 4-(methylthio)phenylboronic acid. After purification, a pale yellow solid was obtained (30 mg, 40%): Melting point 194.0 – 197.0 °C.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.95 (s, 1H), 8.93 (s, 1H), 8.07 (s, 1H), 7.91 (d,  $J = 8.2$  Hz, 2H), 7.40 (d,  $J = 8.2$  Hz, 2H), 4.25 (s, 2H), 2.55 (s, 3H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.4, 160.9, 159.6, 154.1, 151.3, 141.8, 128.1, 127.1, 126.5, 126.0, 119.4, 31.5, 14.2. HRMS (HESI) calcd for  $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_2\text{S}_3$   $[\text{M}+\text{H}]^+$  349.0139, found 349.0121.

**2-((6-(4-Chlorophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11a).** Prepared using general procedure A, with (4-chlorophenyl)boronic acid. After purification, a white solid was obtained (40 mg, 55%): Melting point >250.0 °C.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.95 (s, 1H), 8.96 (s, 1H), 8.16 (s, 1H), 8.01 (d,  $J = 8.4$  Hz, 2H), 7.62 (d,  $J = 8.4$  Hz, 2H), 4.26 (s, 2H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.3, 161.3, 159.3, 154.1, 150.1, 135.0, 130.8, 129.4, 128.5, 127.0, 120.8, 31.5. HRMS (HESI) calcd for  $\text{C}_{14}\text{H}_9\text{ClN}_2\text{O}_2\text{S}_2$   $[\text{M}+\text{H}]^+$  336.9872, found 336.9849.

**2-((6-(3-(Methylthio)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11b).** Prepared using general procedure A, with 3-(methylthio)phenylboronic acid. After purification, a pale yellow solid was obtained (48 mg, 65%): Melting point >250.0 °C.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.88 (s, 1H), 8.11 (s, 1H), 7.78 (t,  $J = 1.8$  Hz, 1H), 7.68 (dt,  $J = 7.5, 1.3$  Hz, 1H), 7.47 (t,  $J = 7.8$  Hz, 1H), 7.41 – 7.35 (m, 1H), 3.92 (s, 2H), 2.58 (s, 3H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  171.0, 158.7, 154.1, 150.3, 144.4, 140.0, 132.8, 129.8, 127.4, 127.0, 123.3, 123.1, 120.7, 28.9, 14.5. HRMS (HESI) calcd for  $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_2\text{S}_3$   $[\text{M}+\text{H}]^+$  349.0139, found 349.0124.

**2-((6-(2-Methoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11c).** Prepared using general procedure A, with 2-methoxyphenylboronic acid. After purification, a whitish solid was obtained (35 mg, 50%): Melting point 219.0 – 221.5 °C.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.93 (s, 1H), 8.93 (s, 1H), 8.11 (s, 1H), 8.07 – 8.04 (m, 1H), 7.51 (ddd,  $J = 8.6, 7.5, 1.7$  Hz, 1H), 7.28 (dd,  $J = 8.6, 1.1$  Hz, 1H), 7.13 (td,  $J = 7.5, 1.1$  Hz, 1H), 4.26 (s, 2H), 4.02 (s, 3H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.4, 160.8, 158.1, 156.1, 153.7, 147.3,

131.6, 129.1, 127.4, 121.2, 121.0, 120.2, 112.6, 56.0, 31.4. HRMS (HESI) calcd for C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [M+H]<sup>+</sup> 333.0367, found 333.0345.

**2-((6-(4-(Isopropylthio)phenyl)thieno[3,2-d]pyrimidin-4-yl)thio)acetic acid (11d).** Prepared using general procedure A, with 4-(isopropylthio)phenylboronic acid. After purification, a pale yellow solid was obtained (36 mg, 45%): Melting point 234.0 – 237.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.86 (s, 1H), 8.02 (s, 1H), 7.89 (d, *J* = 8.1 Hz, 2H), 7.47 (d, *J* = 8.1 Hz, 2H), 3.95 (s, 2H), 3.67 (sept, *J* = 6.8 Hz, 1H), 1.30 (d, *J* = 6.8 Hz, 6H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 163.5, 158.9, 154.1, 153.6, 150.3, 138.8, 135.8, 129.6, 129.4, 127.1, 126.7, 124.3, 119.8, 40.0, 36.1, 22.7. HRMS (HESI) calcd for C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S<sub>3</sub> [M+H]<sup>+</sup> 377.0452, found 377.0433.

**2-((6-(4-Ethylphenyl)thieno[3,2-d]pyrimidin-4-yl)thio)acetic acid (11e).** Prepared using general procedure A, with 4-ethylphenylboronic acid. After purification, a whitish solid was obtained (28 mg, 40%): Melting point 175.0 – 177.5 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.94 (s, 1H), 8.94 (s, 1H), 8.05 (s, 1H), 7.89 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 8.0 Hz, 2H), 4.26 (s, 2H), 2.68 (q, *J* = 7.5 Hz, 2H), 1.21 (d, *J* = 7.5 Hz, 3H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.3, 160.9, 159.5, 154.0, 151.9, 146.6, 129.4, 128.8, 126.8, 126.6, 119.4, 31.4, 27.9, 15.3. HRMS (HESI) calcd for C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 331.0574, found 331.0561.

**2-((6-(4-Vinylphenyl)thieno[3,2-d]pyrimidin-4-yl)thio)acetic acid (11f).** Prepared using general procedure A, with 4-vinylphenylboronic acid. After purification, a pale yellow solid was obtained (43 mg, 62%): Melting point 198.0 – 201.0 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.95 (s, 1H), 8.95 (s, 1H), 8.13 (s, 1H), 7.96 (d, *J* = 8.4 Hz, 1H), 7.65 (d, *J* = 8.4 Hz, 1H), 6.82 (dd, *J* = 17.7, 10.9 Hz, 1H), 5.99 (d, *J* = 17.7 Hz, 1H), 5.39 (d, *J* = 10.9 Hz, 1H), 4.26 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.3, 161.0, 159.4, 154.1, 151.2, 139.0, 135.7, 131.2, 127.0, 127.0, 126.8, 120.0, 116.1, 31.5. HRMS (HESI) calcd for C<sub>16</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 329.0418, found 329.0401.

**2-((6-(4-Isopropylphenyl)thieno[3,2-d]pyrimidin-4-yl)thio)acetic acid (11g).** Prepared using general procedure A, with 4-isopropylphenylboronic acid. After purification, a whitish solid was obtained (40 mg, 55%): Melting point 154 – 159 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.94 (s, 1H), 8.94 (s, 1H), 8.05 (s, 1H), 7.92 – 7.87 (m, 2H), 7.45 – 7.40 (m, 2H), 4.26 (s, 2H), 3.00 – 2.94 (sept, *J* = 6.9 Hz, 1H), 1.24 (d, *J* = 6.9 Hz, 6H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.4, 161.0, 159.5, 154.0, 151.9, 151.1, 129.6, 127.4, 126.8, 126.6, 119.5, 33.3, 31.5, 23.6. HRMS (HESI) calcd for C<sub>17</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 345.0731, found 345.0707.

**2-((6-(4-Cyclopropylphenyl)thieno[3,2-d]pyrimidin-4-yl)thio)acetic acid (11h).** Prepared using general procedure A, with 4-cyclopropylphenylboronic acid. After purification, a whitish solid was obtained (35 mg, 48%): Melting point 184.0 – 187.0 °C. <sup>1</sup>H NMR (700 MHz, DMSO-*d*<sub>6</sub>) δ 12.94 (s, 1H), 8.93 (s, 1H), 8.03 (s, 1H), 7.84 (d, *J* = 8.3 Hz, 2H), 7.23 (d, *J* = 8.3 Hz, 2H), 4.25 (s, 2H), 2.03 – 1.98 (m, 1H), 1.05 – 1.01 (m, 2H), 0.79 – 0.75 (m, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.3, 160.8, 159.5, 154.0, 151.8, 146.9, 128.9, 126.6, 126.5, 126.2, 119.2, 31.4, 15.1, 10.1. HRMS (HESI) calcd for C<sub>17</sub>H<sub>14</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 343.0574, found 343.0558.

**2-((6-(3,4-Dichlorophenyl)thieno[3,2-d]pyrimidin-4-yl)thio)acetic acid (11i).** Prepared using general procedure A, with 3,4-dichlorophenylboronic acid. After purification, a white solid was obtained (31 mg, 40%): Melting point 222.0 – 226.0 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.96 (s, 1H), 8.98 (s, 1H), 8.32 (d, *J* = 2.2 Hz, 1H), 8.27 (s, 1H), 7.95 (dd, *J* = 8.4, 2.2 Hz, 1H), 7.81 (d, *J* = 8.4 Hz, 1H), 4.27 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.2, 161.5, 159.1, 154.1, 148.5, 132.8, 132.5, 132.3, 131.4, 128.4, 127.2, 126.8, 121.9, 31.5. (HESI) calcd for C<sub>14</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 372.9453, found 372.9438.

**2-((6-(4-(Benzyloxy)phenyl)thieno[3,2-d]pyrimidin-4-yl)thio)acetic acid (11j).** Prepared using general procedure A, with 4-(Benzyloxy)phenylboronic acid. After purification, a pale yellow solid was obtained (26 mg, 30%): Melting point 192.0 – 195.0 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.93 (bs, 0.5H), 11.95 (bs, 0.5H), 8.92 (s, 1H), 7.98 (s, 1H), 7.94 – 7.91 (m, 2H), 7.48 (d, *J* = 7.5 Hz, 2H), 7.42 (dd, *J* = 8.3, 6.8 Hz, 2H),



7.36 (d,  $J = 7.5$  Hz, 1H), 7.19 – 7.16 (m, 2H), 5.22 (s, 2H), 4.25 (s, 2H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.3, 160.6, 160.1, 159.7, 154.0, 151.7, 136.6, 128.5, 128.3, 127.9, 127.7, 126.4, 124.6, 118.5, 115.6, 69.4, 31.4. HRMS (HESI) calcd for  $\text{C}_{21}\text{H}_{16}\text{N}_2\text{O}_3\text{S}_2$   $[\text{M}+\text{H}]^+$  409.0680, found 409.0671.

**2-((6-(4-Acetamidophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11k).** Prepared using general procedure A, with 4-acetamidophenylboronic acid. After purification, a pale yellow solid was obtained (23 mg, 30%): Melting point 232.0 – 235.0 °C.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.94 (s, 1H), 10.23 (s, 1H), 8.92 (s, 1H), 7.99 (s, 1H), 7.94 – 7.88 (m, 2H), 7.77 – 7.72 (m, 2H), 4.25 (s, 2H), 2.09 (s, 3H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.4, 168.7, 160.8, 159.6, 154.0, 151.7, 141.3, 127.4, 126.4, 126.3, 119.2, 118.7, 31.5, 24.2. HRMS (HESI) calcd for  $\text{C}_{16}\text{H}_{13}\text{N}_3\text{O}_3\text{S}_2$   $[\text{M}+\text{H}]^+$  360.0476, found 360.0463.

**2-((6-(3-Acetamidophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11l).** Prepared using general procedure A, with 3-acetamidophenylboronic acid. After purification, a pale yellow solid was obtained (26 mg, 35%): Melting point 221.0 – 225.0 °C.  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  12.96 (s, 1H), 10.18 (s, 1H), 8.96 (s, 1H), 8.21 – 8.17 (m, 1H), 8.01 (s, 1H), 7.68 (ddd,  $J = 11.1, 7.9, 1.9$  Hz, 2H), 7.48 (t,  $J = 7.9$  Hz, 1H), 4.27 (s, 2H), 3.32 (s, 3H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.4, 168.7, 161.2, 159.3, 154.1, 151.6, 140.2, 132.2, 130.0, 126.7, 121.4, 120.6, 120.1, 116.7, 31.5, 24.1. HRMS (HESI) calcd for  $\text{C}_{16}\text{H}_{13}\text{N}_3\text{O}_3\text{S}_2$   $[\text{M}+\text{H}]^+$  360.0476, found 360.0454.

**2-((6-(4-(Methylsulfinyl)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11m).** Prepared using general procedure A, with 4-(methylsulfinyl)phenylboronic acid. After purification, a whitish solid was obtained (34 mg, 45%): Melting point 220.0 – 222.5 °C.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.94 (s, 1H), 8.98 (s, 1H), 8.24 (s, 1H), 8.20 – 8.16 (m, 2H), 7.87 – 7.83 (m, 2H), 4.27 (s, 2H), 2.82 (s, 3H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.3, 161.4, 159.2, 154.2, 150.2, 148.5, 133.9, 127.5, 127.1, 124.7, 121.4, 43.1, 31.5. HRMS (HESI) calcd for  $\text{C}_{15}\text{H}_{12}\text{N}_2\text{O}_3\text{S}_3$   $[\text{M}+\text{H}]^+$  365.0088, found 365.0071.

**2-((6-(4-Acetylphenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11n).** Prepared using general procedure A, with 4-acetylphenylboronic acid. After purification, a whitish solid was obtained (40 mg, 55%): Melting point 193.0 – 197.0 °C.  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  12.97 (s, 1H), 8.99 (s, 1H), 8.29 (s, 1H), 8.14 (d,  $J = 8.5$  Hz, 2H), 8.10 (d,  $J = 8.5$  Hz, 2H), 4.28 (s, 2H), 2.65 (s, 3H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  197.3, 169.3, 161.5, 159.2, 154.2, 150.0, 137.6, 135.9, 129.2, 127.4, 127.0, 121.9, 31.5, 26.9. HRMS (HESI) calcd for  $\text{C}_{16}\text{H}_{12}\text{N}_2\text{O}_3\text{S}_2$   $[\text{M}+\text{H}]^+$  345.0367, found 345.0357.

**2-((6-(3-Morpholinophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11o).** Prepared using general procedure A, with 3-morpholinophenylboronic acid. After purification, a pale orange solid was obtained (29 mg, 35%): Melting point 229.0 – 233.0 °C.  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  12.94 (s, 1H), 8.95 (s, 1H), 8.13 (s, 1H), 7.46 (t,  $J = 2.1$  Hz, 1H), 7.41 – 7.34 (m, 2H), 7.12 – 7.07 (m, 1H), 4.26 (s, 2H), 3.77 (dd,  $J = 5.8, 3.8$  Hz, 4H), 3.26 – 3.23 (m, 4H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.3, 161.0, 159.4, 154.0, 152.4, 151.7, 132.6, 130.1, 126.7, 120.0, 117.3, 116.9, 112.7, 66.0, 48.0, 31.4. HRMS (HESI) calcd for  $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_3\text{S}_2$   $[\text{M}+\text{H}]^+$  388.0789, found 388.0780.

**2-((6-(4-Morpholinophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11p).** Prepared using general procedure A, with 4-morpholinophenylboronic acid. After purification, an orange solid was obtained (29 mg, 35%): Melting point 205.0 – 208.0 °C.  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  12.92 (s, 1H), 8.88 (s, 1H), 7.89 (s, 1H), 7.82 (d,  $J = 8.9$  Hz, 2H), 7.06 (d,  $J = 8.9$  Hz, 2H), 4.24 (s, 2H), 3.78 – 3.72 (m, 4H), 3.28 – 3.23 (m, 4H);  $^{13}\text{C}$  NMR (176 MHz, DMSO)  $\delta$  169.5, 160.2, 159.9, 154.0, 152.5, 152.3, 127.8, 125.9, 121.8, 117.1, 114.6, 65.9, 47.2, 31.4. HRMS (HESI) calcd for  $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_3\text{S}_2$   $[\text{M}+\text{H}]^+$  388.0790, found 388.0773.

**2-((6-(6-Acetylpyridin-3-yl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11q).** Prepared using general procedure A, with (6-acetylpyridin-3-yl)phenylboronic acid. After purification, a pale orange solid was obtained (22 mg, 30%): Melting point 181.0 – 184.0 °C.  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.98 (s, 1H), 9.36 (d,  $J = 2.4$  Hz, 1H), 9.01 (s, 1H), 8.55 (dd,  $J = 8.2, 2.4$  Hz, 1H), 8.41 (s, 1H), 8.08 (d,  $J = 8.2$  Hz, 1H), 4.29 (s,

2H), 2.69 (s, 3H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 198.6, 169.2, 161.8, 158.9, 154.2, 153.2, 147.0, 146.8, 135.3, 131.2, 127.7, 123.1, 121.5, 31.6, 25.7. HRMS (HESI) calcd for C<sub>15</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub>S<sub>2</sub> [M+H]<sup>+</sup> 346.0320, found 346.0310.

**2-((6-(Thiophen-2-yl)thieno[3,2-d]pyrimidin-4-yl)thio)acetic acid (11r).** Prepared using general procedure A, with 2-thienylboronic acid. After purification, a pale orange solid was obtained (29 mg, 45%): Melting point 179.0 – 182.0 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.95 (s, 1H), 8.93 (s, 1H), 7.85 (s, 1H), 7.83 (dd, *J* = 5.0, 1.2 Hz, 1H), 7.80 (dd, *J* = 3.7, 1.2 Hz, 1H), 7.26 – 7.23 (m, 1H), 4.25 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.4, 160.9, 159.3, 154.3, 144.7, 134.7, 129.8, 129.0, 128.3, 126.3, 119.3, 31.5. HRMS (HESI) calcd for C<sub>12</sub>H<sub>8</sub>N<sub>2</sub>O<sub>2</sub>S<sub>3</sub> [M+H]<sup>+</sup> 308.9826, found 308.9811.

**2-((6-(Benzo[*b*]thiophen-2-yl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11s).** Prepared using general procedure A, with benzo[*b*]thien-2-ylboronic acid. After purification, a pale orange solid was obtained (30 mg, 40%): Melting point >250 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.97 (s, 1H), 8.98 (s, 1H), 8.16 (s, 1H), 8.08 – 8.06 (m, 1H), 7.98 (s, 1H), 7.96 – 7.93 (m, 1H), 7.48 – 7.46 (m, 2H), 4.27 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.3, 161.2, 159.0, 154.3, 144.4, 139.6, 134.4, 126.9, 126.3, 125.4, 124.8, 124.7, 122.7, 121.2, 31.6. HRMS (HESI) calcd for C<sub>16</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>S<sub>3</sub> [M+H]<sup>+</sup> 358.9982, found 358.9971.

**2-((6-(4-Cyanophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11t).** Prepared using general procedure A, with 4-cyanophenylboronic acid. After purification, a pale brown solid was obtained (34 mg, 50%): Melting point 226.0 – 230.0 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.97 (s, 1H), 8.99 (s, 1H), 8.33 (s, 1H), 8.19 – 8.17 (m, 2H), 8.03 – 7.99 (m, 2H), 4.27 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.6, 162.1, 159.1, 154.4, 149.6, 136.4, 133.5, 128.0, 127.8, 122.6, 118.6, 112.6, 31.8. HRMS (HESI) calcd for C<sub>15</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 328.0214, found 328.0190.

**2-((6-(4-(Ethoxycarbonyl)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11u).** Prepared using general procedure A, with 4-ethoxycarbonylphenylboronic acid. After purification, a pale orange solid was obtained (39 mg, 50%): Melting point 182.0 – 185.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.96 (s, 1H), 8.97 (s, 1H), 8.25 (s, 1H), 8.12 (d, *J* = 8.4 Hz, 2H), 8.06 (d, *J* = 8.4 Hz, 2H), 4.33 (q, *J* = 7.1 Hz, 2H), 4.25 (s, 2H), 1.34 (t, *J* = 7.1 Hz, 3H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.3, 165.0, 161.6, 159.1, 154.1, 149.8, 136.0, 130.9, 130.0, 127.3, 127.0, 121.9, 61.0, 31.6, 14.1. HRMS (HESI) calcd for C<sub>17</sub>H<sub>14</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub> [M+H]<sup>+</sup> 375.0473, found 375.0445.

**2-((6-(3-Fluorophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11v).** Prepared using general procedure A, with 3-fluorophenylboronic acid. After purification, a white solid was obtained (39 mg, 58%): Melting point 194.0 – 196.5 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.96 (s, 1H), 8.97 (s, 1H), 8.22 (s, 1H), 7.91 (dt, *J* = 10.2, 2.2 Hz, 1H), 7.80 (dd, *J* = 7.7, 1.6 Hz, 1H), 7.60 (td, *J* = 8.0, 6.0 Hz, 1H), 7.38 (dd, *J* = 8.6, 2.6 Hz, 1H), 4.27 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO-*d*<sub>6</sub>) δ 169.2, 162.5 (d, *J* = 246.3 Hz), 161.5, 159.1, 154.1, 149.9 (d, *J* = 2.8 Hz), 134.1 (d, *J* = 8.4 Hz), 131.5 (d, *J* = 8.5 Hz), 127.1, 122.9 (d, *J* = 2.5 Hz), 121.3, 117.1 (d, *J* = 21.3 Hz), 113.6 (d, *J* = 23.7 Hz), 31.6; <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>) δ -111.82 – -111.92 (m, 1F). HRMS (HESI) calcd for C<sub>14</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 321.0167, found 321.0151.

**2-((6-(2-Fluorophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11w).** Prepared using general procedure A, with 2-fluorophenylboronic acid. After purification, a white solid was obtained (40 mg, 60%): Melting point 184.0 – 187.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.96 (s, 1H), 8.99 (s, 1H), 8.13 – 8.07 (m, 2H), 7.58 (s, 1H), 7.49 (dd, *J* = 11.7, 1.2 Hz, 1H), 7.43 – 7.39 (m, 1H), 4.27 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO-*d*<sub>6</sub>) δ 169.3, 161.5, 158.9 (d, *J* = 149.4 Hz), 158.4, 154.1, 144.3 (d, *J* = 3.5 Hz), 132.3 (d, *J* = 8.8 Hz), 129.8, 127.2 (d, *J* = 5.3 Hz), 125.6 (d, *J* = 3.2 Hz), 122.9 (d, *J* = 4.8 Hz), 119.7 (d, *J* = 11.7 Hz), 116.8 (d, *J* = 22.0 Hz); <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>) δ -112.35 – -112.50 (m, 1F). HRMS (HESI) calcd for C<sub>14</sub>H<sub>9</sub>FN<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 321.0167, found 321.0142.

**2-((6-(3,4-Difluorophenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11x).** Prepared using general procedure A, with 3,4-difluorophenylboronic acid. After purification, a white solid was obtained (32 mg, 45%): Melting point 206.0 – 209.0 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.96 (s, 1H), 8.97 (s, 1H), 8.20 – 8.16 (m, 2H), 7.83 (dd, *J* = 8.2, 3.9 Hz, 1H), 7.66 – 7.60 (m, 1H), 4.27 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.3, 161.3, 159.1, 154.1, 150.9 (dd, *J* = 120.7, 12.8 Hz), 149.5 (dd, *J* = 117.2, 12.8 Hz), 149.0, 129.6 – 129.5 (m), 127.1, 124.1 – 123.9 (m), 121.3, 118.6 (d, *J* = 17.7 Hz), 116.1 (d, *J* = 18.8 Hz), 31.5; <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>) δ -135.61 – -135.88 (m, 1F), -136.89 – -137.13 (m, 1F). HRMS (HESI) calcd for C<sub>14</sub>H<sub>8</sub>F<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 339.0073, found 339.0058.

**2-((6-(3-Fluoro-4-(methylthio)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11y)** Prepared using general procedure A, with 3-fluoro-4-(methylthio)phenylboronic acid. After purification, a pale yellow solid was obtained (32 mg, 42%): Melting point 203.0 – 206.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.95 (s, 1H), 8.95 (s, 1H), 8.17 (s, 1H), 7.92 (dd, *J* = 11.4, 2.0 Hz, 1H), 7.80 (dd, *J* = 8.1, 2.0 Hz, 1H), 7.51-7.44 (m, 1H), 4.26 (s, 2H), 2.57 (s, 3H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.3, 161.1, 159.3, 158.6 (d, *J* = 242.1 Hz), 154.1, 149.8 (d, *J* = 2.5 Hz), 129.9 (d, *J* = 8.1 Hz), 128.7 (d, *J* = 17.1 Hz), 127.3 (d, *J* = 3.3 Hz), 126.8, 123.3 (d, *J* = 2.8 Hz), 120.6, 112.9 (d, *J* = 23.4 Hz), 31.5, 13.5; <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>) δ -112.48 (dd, *J* = 11.4, 8.1 Hz). HRMS (HESI) calcd for C<sub>15</sub>H<sub>11</sub>FN<sub>2</sub>O<sub>2</sub>S<sub>3</sub> [M+H]<sup>+</sup> 367.0044, found 367.0027.

**2-((6-(3-Fluoro-4-methoxyphenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11z).** Prepared using general procedure A, with 3-fluoro-4-methoxyphenylboronic acid. After purification, a pale yellow solid was obtained (29 mg, 40%): Melting point 209.0 – 211.5 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.94 (s, 1H), 8.93 (s, 1H), 8.06 (s, 1H), 7.95 (dd, *J* = 12.5, 2.4 Hz, 1H), 7.77 – 7.74 (m, 1H), 7.35 – 7.28 (m, 1H), 4.25 (s, 2H), 3.93 (s, 3H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.4, 160.9, 159.5, 154.1, 151.6 (d, *J* = 245.4 Hz), 150.4 (d, *J* = 2.4 Hz), 148.9 (d, *J* = 10.6 Hz), 126.6, 124.8 (d, *J* = 7.1 Hz), 123.6 (d, *J* = 3.1 Hz), 119.6, 114.3, 114.3 (d, *J* = 17.8 Hz), 56.2, 31.5; <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>) δ -134.17 (dd, *J* = 12.5, 9.2 Hz). HRMS (HESI) calcd for C<sub>15</sub>H<sub>11</sub>FN<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [M+H]<sup>+</sup> 351.0273, found 351.0260.

**2-((6-(4-(Trifluoromethyl)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11aa).** Prepared using general procedure A, with 4-(trifluoromethyl)phenylboronic acid. After purification, a pale orange solid was obtained (39 mg, 50%): Melting point 173.0 – 176.0 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 9.00 (s, 1H), 8.30 (s, 1H), 8.21 (d, *J* = 8.4 Hz, 2H), 7.91 (d, *J* = 8.4 Hz, 2H), 4.28 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.2, 161.6, 159.1, 154.2, 149.4, 135.7, 130.0 (q, *J* = 32.0 Hz), 127.6, 127.4, 126.3 (q, *J* = 3.7 Hz), 123.9 (q, *J* = 272.0 Hz), 122.2, 31.6; <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>) δ -61.35. HRMS (HESI) calcd for C<sub>15</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 371.0135, found 371.0118.

**2-((6-(3-(Trifluoromethoxy)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetic acid (11ab).** Prepared using general procedure A, with 3-(trifluoromethoxy)phenylboronic acid. After purification, a whitish solid was obtained (41 mg, 50%): Melting point 210.0 – 213.0 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.96 (s, 1H), 8.98 (s, 1H), 8.27 (s, 1H), 8.04 – 7.98 (m, 2H), 7.71 – 7.66 (m, 1H), 7.53 (d, *J* = 8.2 Hz, 1H), 4.27 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.3, 161.5, 159.1, 154.1, 149.4, 149.0 (d, *J* = 1.8 Hz), 134.1, 131.5, 127.2, 125.9, 122.5, 121.7, 120.0 (q, *J* = 258.4 Hz), 119.4, 31.5; <sup>19</sup>F NMR (376 MHz, DMSO-*d*<sub>6</sub>) δ -56.74. HRMS (HESI) calcd for C<sub>15</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [M+H]<sup>+</sup> 387.0085, found 387.0071.

**2-((6-(4-(Methylthio)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)thio)acetamide (12).** Into a 20 mL vial provided with a magnetic stir bar, reagents were loaded in the following order: compound (4) (1.0 equiv, 0.06 mmol, 20 mg), DMF (1.0 mL), *N,N*-diisopropylethylamine (2.2 equiv, 0.13 mmol, 20 mg), HATU (1.0 equiv, 0.06 mmol, 23 mg), and ammonia (excess, 0.1 mL of an 28% aqueous solution). The vial was sealed and the reaction mixture stirred at room temperature for 12 h. It was quenched with water, solid slowly precipitated, filtered, thoroughly rinsed with water, air and vacuum dried. No further purification was needed, yielding a pale brown solid (5 mg, 25%): Melting point 231.0 – 234.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.93 (s, 1H), 8.06 (s, 1H), 7.92 – 7.89 (m, 2H), 7.69 (s, 1H), 7.42 – 7.39 (m, 2H), 7.24 (s, 1H), 4.16 (s,

2H), 2.55 (s, 3H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 168.4, 161.4, 159.4, 154.0, 151.2, 141.7, 128.1, 127.0, 126.6, 126.0, 119.3, 32.9, 14.2. HRMS (HESI) calcd for C<sub>15</sub>H<sub>13</sub>N<sub>3</sub>OS<sub>3</sub> [M+H]<sup>+</sup> 348.0299, found 348.0279.

**General procedure B. Synthesis of 4-chloro-6-arylthieno[3,2-*d*]pyrimidines (13a-b).** In a 50 mL round bottom flask provided with a reflux condenser, a rubber septum, a magnetic stir bar, and under positive N<sub>2</sub> pressure the following reagent were added: 4-chloro-6-iodothieno[3,2-*d*]pyrimidine **10** (1.0 equiv, 1.20 mmol, 355 mg), NaHCO<sub>3</sub> (1.0 equiv, 1.20 mmol, 100 mg), CsF (1.0 equiv, 1.20 mmol, 185 mg), Pd(Ph<sub>3</sub>)<sub>4</sub> (3 mol%, 40 mg) and the corresponding arylboronic acid (1.0 equiv, 1.20 mmol). A previously N<sub>2</sub> degassed solution of 1,4-dioxane/water (3:1, 7.0 mL) was added and the reaction mixture was stirred under mild reflux for 3 h. After this period, solvent was removed under reduced pressure and the resulting solid was purified over silica gel with hexanes/EtOAc in a gradient up to 30% of the polar solvent.

**7-Chloro-2-(4-chlorophenyl)benzo[*b*]thiophene (13a).** Prepared using general procedure B, with (4-chlorophenyl)boronic acid. After purification, a white solid was obtained (185 mg, 55%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.97 (s, 1H), 7.74 (s, 1H), 7.73 – 7.69 (m, 2H), 7.53 – 7.47 (m, 2H).

**7-Chloro-2-(4-(methylthio)phenyl)benzo[*b*]thiophene (13b).** Prepared using general procedure B, with (4-(methylthio)phenyl)boronic acid. After purification, a pale yellow solid was obtained (300 mg, 85%): <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 9.01 (s, 1H), 8.21 (s, 1H), 7.97 – 7.90 (m, 2H), 7.44 – 7.38 (m, 2H), 2.56 (s, 3H).

**Ethyl 2-((6-(4-chlorophenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)acetate (14).** Into a 20 mL microwave vial provided with a magnetic stir bar, reagents were loaded in the following order: 7-chloro-2-(4-chlorophenyl)benzo[*b*]thiophene **13a** (1.0 equiv, 0.23 mmol, 65 mg), anhydrous DMF (3.0 mL), ethyl 2-hydroxyacetate (2.0 equiv, 0.46 mmol, 48 mg), and NaH (2.6 equiv, 0.60 mmol, 25 mg, 60% dispersion in mineral oil). The vial was sealed and the reaction mixture stirred at 100 °C for 30 min in a microwave reactor. The crude was quenched over ice/water, solvents were evaporated in vacuo, and purified over silica gel with hexanes/EtOAc in a gradient up to 50% of EtOAc. After purification, a white solid was recovered (37 mg, 45%): Melting point 145.0 – 148.0 °C. <sup>1</sup>H NMR (700 MHz, DMSO-*d*<sub>6</sub>) δ 8.75 (s, 1H), 8.12 (s, 1H), 7.97 (dd, *J* = 8.6, 2.4 Hz, 2H), 7.63 – 7.59 (m, 2H), 5.21 (s, 2H), 4.18 (q, *J* = 8.2 Hz, 2H), 1.20 (t, *J* = 8.2 Hz, 3H). <sup>13</sup>C NMR (176 MHz, DMSO) δ 167.6, 162.8, 162.3, 154.3, 150.5, 134.8, 131.0, 129.3, 128.3, 120.8, 115.9, 62.8, 60.8, 13.9. HRMS (HESI) calcd for C<sub>16</sub>H<sub>14</sub>N<sub>2</sub>O<sub>3</sub>SCl [M+H]<sup>+</sup> 349.0335, found 349.0400.

**2-((6-(4-Chlorophenyl)thieno[3,2-*d*]pyrimidin-4-yl)oxy)acetic acid (15).** In a 10 mL round bottom flask provided with a reflux condenser and a magnetic stir bar, compound **14** (1.0 equiv, 0.06 mmol, 21 mg) was dissolved in THF (2 mL), followed by the addition of LiOH (2.2 equiv, 0.12 mmol, 3 mg) pre-dissolved in water. This mixture was refluxed at 70 °C for 4–5 h. Solvents were removed under reduced pressure and the white solid obtained was taken into ice/water and the pH adjusted to 3–4 with 2M HCl<sub>(aq)</sub>. The resulting solid was filtrated, thoroughly rinsed with water, and air/vacuum dried yielding a white solid (16 mg, 82%): Melting point 234.0 – 236.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 13.20 (s, 1H), 8.76 (s, 1H), 8.13 (s, 1H), 7.98 (d, *J* = 8.5 Hz, 2H), 7.62 (d, *J* = 8.5 Hz, 2H), 5.12 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.1, 162.8, 162.5, 154.4, 150.4, 134.8, 131.1, 129.4, 128.3, 120.8, 116.1, 62.8. HRMS (HESI) calcd for C<sub>14</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>3</sub>S [M+H]<sup>+</sup> 321.0100, found 321.0080.

**Ethyl (6-(4-(methylthio)phenyl)thieno[3,2-*d*]pyrimidin-4-yl)glycinate (16).** Into a 20 mL vial provided with a magnetic stir bar, reagents were loaded in the following order: compound **13b** (1.0 equiv, 0.27 mmol, 80 mg), EtOH (5.0 mL), ethyl glycinate hydrochloride (2.5 equiv, 0.68 mmol, 95 mg), and triethylamine (10 equiv, 2.7 mmol, 0.4 mL). The vial was sealed and the reaction mixture stirred at 90 °C for 18 h. After this period, solvent was evaporated in vacuo, and purified over silica gel with hexanes/EtOAc in a gradient up to 60% of EtOAc. After purification, a pale yellow solid was recovered (85 mg, 78%): Melting point 160.5 – 164.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.43 (s, 1H), 8.33 (s, 1H), 7.82

(s, 1H), 7.80 (d,  $J = 8.4$  Hz, 2H), 7.39 (d,  $J = 8.4$  Hz, 2H), 4.21 (d,  $J = 5.9$  Hz, 2H), 4.13 (q,  $J = 7.1$  Hz, 2H), 2.54 (s, 3H), 1.20 (t,  $J = 7.1$  Hz, 3H). HRMS (HESI) calcd for  $C_{17}H_{18}N_3O_2S_2$   $[M+H]^+$  360.0762, found 360.0844.

**2-((6-Bromothieno[2,3-*d*]pyrimidin-4-yl)thio)acetic acid (18).** In a 50 mL round bottom flask provided with a rubber septum, a magnetic stir bar, and under positive  $N_2$  pressure, 6-bromo-4-chlorothieno[2,3-*d*]pyrimidine (1.0 equiv, 4.0 mmol, 1.0 g) **17** was suspended in  $CH_3CN$  or EtOH (15 mL) at  $0^\circ C$  (ice bath), followed by the dropwise addition of 2-mercaptoacetic acid (1.25 equiv, 5.0 mmol, 0.35 mL) and triethylamine (2.5 equiv, 10.0 mmol, 1.4 mL). Ice bath was removed and the reaction mixture was stirred overnight at room temperature. After this period, solvent was removed under reduced pressure, solid taken into ice/water, and the pH adjusted to 2–3 with 2M aq. HCl. The resulting solid was filtrated, thoroughly rinsed with water, air and vacuum dried, yielding a white solid. No further purification was needed (0.91 g, 75%). Melting point  $194.5 - 198.0^\circ C$ .  $^1H$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.90 (s, 1H), 8.83 (s, 1H), 7.83 (s, 1H), 4.18 (s, 2H);  $^{13}C$  NMR (176 MHz, DMSO)  $\delta$  169.3, 165.9, 161.6, 152.6, 128.0, 122.1, 116.2, 31.4. HRMS (HESI) calcd for  $C_8H_6N_2O_2S_2Br$   $[M+H]^+$  304.8976, found 304.9059.

**General procedure C. Synthesis of 6-Arylthieno[2,3-*d*]pyrimidines (19a-g).** In a 25 mL round bottom flask provided with a reflux condenser, a rubber septum, a magnetic stir bar, and under positive  $N_2$  pressure the following reagent were added: 2-((6-bromothieno[2,3-*d*]pyrimidin-4-yl)thio)acetic acid (**18**) (1.0 equiv, 0.25 mmol, 75 mg),  $K_2CO_3$  (4.0 equiv, 1.0 mmol, 140 mg),  $Pd(Ph_3)_4$  (5 mol%, 15 mg) and the corresponding arylboronic acid (1.0 equiv, 0.25 mmol). A previously  $N_2$  degassed solution of 1,4-dioxane/water (3:1, 2.5 mL) was added and the reaction mixture was stirred under mild reflux for 3 h. After this period, solvent was removed under reduced pressure, solids taken into ice/water, and the pH adjusted to 2-3 with 2M  $HCl_{(aq)}$ . The resulting solid was filtrated, thoroughly rinsed with water, air and vacuum dried, and purified over silica gel using  $CH_2Cl_2/MeOH/HOAc$  (95/4/1) in a gradient up 5-10% of the polar solvent.

**2-((6-(4-(Methylthio)phenyl)thieno[2,3-*d*]pyrimidin-4-yl)thio)acetic acid (19a).** Prepared using general procedure C, with 4-(methylthio)phenylboronic acid. After purification, a pale yellow solid was obtained (45 mg, 53%): Melting point  $194.0 - 196.5^\circ C$ .  $^1H$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.89 (s, 1H), 8.81 (s, 1H), 7.91 (s, 1H), 7.85 (d,  $J = 8.6$  Hz, 2H), 7.38 (d,  $J = 8.6$  Hz, 2H), 4.20 (s, 2H), 2.54 (s, 3H);  $^{13}C$  NMR (176 MHz, DMSO)  $\delta$  169.5, 164.3, 161.9, 152.2, 143.1, 140.5, 128.8, 128.5, 126.9, 126.1, 113.7, 31.4, 14.3. HRMS (HESI) calcd for  $C_{15}H_{12}N_2O_2S_3$   $[M+H]^+$  349.0139, found 349.0112.

**2-((6-(4-Methoxyphenyl)thieno[2,3-*d*]pyrimidin-4-yl)thio)acetic acid (19b).** Prepared using general procedure C, with 4-methoxyphenylboronic acid. After purification, a pale yellow solid was obtained (39 mg, 48%): Melting point  $175.0 - 178.0^\circ C$ .  $^1H$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.88 (s, 1H), 8.79 (s, 1H), 7.87 – 7.83 (m, 2H), 7.79 (s, 1H), 7.09 – 7.05 (m, 2H), 4.20 (s, 2H), 3.83 (s, 3H);  $^{13}C$  NMR (176 MHz, DMSO)  $\delta$  169.5, 164.2, 161.5, 160.3, 151.9, 143.6, 128.9, 128.0, 124.7, 114.7, 112.6, 55.4, 31.4. HRMS (HESI) calcd for  $C_{15}H_{12}N_2O_3S_2$   $[M+H]^+$  333.0367, found 333.0345.

**2-((6-(3-(Methylthio)phenyl)thieno[2,3-*d*]pyrimidin-4-yl)thio)acetic acid (19c).** Prepared using general procedure C, with 3-(methylthio)phenylboronic acid. After purification, a pale yellow solid was obtained (57 mg, 65%): Melting point  $160.0-163.0^\circ C$ .  $^1H$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.90 (s, 1H), 8.83 (s, 1H), 8.04 (s, 1H), 8.05 – 8.03 (m, 1H), 7.66 – 7.59 (m, 1H), 7.45 (dd,  $J = 8.7, 7.8$  Hz, 1H), 7.37 – 7.33 (m, 1H), 4.21 (s, 2H), 2.58 (s, 3H);  $^{13}C$  NMR (176 MHz, DMSO)  $\delta$  169.5, 164.5, 162.4, 152.41, 142.8, 139.9, 132.9, 129.8, 128.6, 126.7, 123.3, 123.2, 115.1, 31.4, 14.5. HRMS (HESI) calcd for  $C_{15}H_{12}N_2O_2S_3$   $[M+H]^+$  349.0139, found 349.0122.

**2-((6-(3-Methoxyphenyl)thieno[2,3-*d*]pyrimidin-4-yl)thio)acetic acid (19d).** Prepared using general procedure C, with 3-methoxyphenylboronic acid. After purification, a pale yellow solid was obtained (42 mg, 50%): Melting point  $185.0 - 188.0^\circ C$ .  $^1H$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  12.89 (s, 1H), 8.82 (s, 1H), 8.01

(s, 1H), 7.50 – 7.47 (m, 1H), 7.45 – 7.40 (m, 2H), 7.09 – 6.99 (m, 1H), 4.22 (s, 2H), 3.87 (s, 3H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.5, 164.4, 162.3, 159.8, 152.3, 143.3, 133.5, 130.5, 128.6, 119.0, 115.6, 114.8, 111.5, 55.4, 31.4. HRMS (HESI) calcd for C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [M+H]<sup>+</sup> 333.0367, found 333.0370.

**2-((6-(2-Methoxyphenyl)thieno[2,3-d]pyrimidin-4-yl)thio)acetic acid (19e).** Prepared using general procedure C, with 2-methoxyphenylboronic acid. After purification, a pale yellow solid was obtained (46 mg, 55%): Melting point 176.5 – 180.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.89 (s, 1H), 8.81 (s, 1H), 7.99 (dd, *J* = 7.8, 1.7 Hz, 1H), 7.91 (s, 1H), 7.46 (ddd, *J* = 8.7, 7.3, 1.7 Hz, 1H), 7.24 (dd, *J* = 8.7, 1.1 Hz, 1H), 7.12 (ddd, *J* = 7.8, 7.3, 1.1 Hz, 1H), 4.21 (s, 2H), 3.98 (s, 3H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.6, 164.9, 161.6, 155.8, 152.0, 139.3, 130.9, 128.8, 127.2, 121.2, 120.6, 115.3, 112.5, 55.9, 31.3. HRMS (HESI) calcd for C<sub>15</sub>H<sub>12</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub> [M+H]<sup>+</sup> 333.0368, found 333.0370.

**2-((6-(3,4-Dichlorophenyl)thieno[2,3-d]pyrimidin-4-yl)thio)acetic acid (19f).** Prepared using general procedure C, with 3,4-dichlorophenylboronic acid. After purification, a white solid was obtained (35 mg, 38%): Melting point >250 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.91 (s, 1H), 8.84 (s, 1H), 8.31 (d, *J* = 2.2 Hz, 1H), 8.17 (s, 1H), 7.86 (dd, *J* = 8.4, 2.2 Hz, 1H), 7.77 (d, *J* = 8.4 Hz, 1H), 4.22 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.5, 164.7, 162.9, 152.6, 140.4, 132.8, 132.2, 131.9, 131.3, 128.5, 128.0, 126.7, 116.5, 31.5. HRMS (HESI) calcd for C<sub>14</sub>H<sub>8</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> [M+H]<sup>+</sup> 370.9482, found 370.9459.

**2-((6-(Benzo[*b*]thiophen-2-yl)thieno[2,3-d]pyrimidin-4-yl)thio)acetic acid (19g).** Melting point 225.0 – 228.0 °C. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 12.92 (s, 1H), 8.85 (s, 1H), 8.06 – 8.02 (m, 2H), 7.95 – 7.90 (m, 1H), 7.80 (s, 1H), 7.46 – 7.43 (m, 2H), 4.23 (s, 2H); <sup>13</sup>C NMR (176 MHz, DMSO) δ 169.4, 164.7, 162.4, 152.7, 139.7, 139.1, 136.6, 134.7, 128.2, 125.9, 125.3, 124.4, 123.9, 122.6, 115.5, 31.5. HRMS (HESI) calcd for C<sub>16</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub>S<sub>3</sub> [M+H]<sup>+</sup> 358.9983, found 358.9988.

**Protein purification and crystallization.** The kinase domain of STK17B (aa 25–329) was expressed as an N-terminal His-tagged fusion in *E. coli*. The recombinant protein was purified by Ni<sup>2+</sup>-affinity chromatography, and subsequently size exclusion chromatography. The protein in 25 mM HEPES, pH 7.5, 500 mM NaCl and 0.5 mM TCEP was mixed with 1 mM inhibitor, and the complex was crystallized using sitting drop vapor diffusion method at 4 °C with the crystallization condition listed in SI Table 3. Crystals were cryo-protected with mother liquor supplemented with 20% ethylene glycol. Diffraction data collected at Diamond Light Source, BESSY II and DESY were processed with iMosflm<sup>43</sup> and scaled with Scala or Aimless from CCP4 suite.<sup>44</sup> The structures were solved by molecular replacement using Phaser<sup>45</sup> and the coordinates of DAPK1 (PDB: 3EHA). Manual model rebuilding was performed in COOT,<sup>46</sup> alternated with refinement using REFMAC5.<sup>47</sup> Data collection and refinement statistics are summarized in SI Table 3.

**Biological assays. Kinase selectivity:** The KINOMEscan scanMAX assay panel was performed at DiscoverX Corporation as previously described<sup>48</sup> across 403 wild type human kinases and 65 mutant human kinases at a compound concentration 1 μM. IC<sub>50</sub> was determined on kinases where an inhibitor displayed >75% inhibition at 1 μM. False positives in the scanMAX assay were identified as those kinases where an inhibitor produced an IC<sub>50</sub> > 10 μM.

**KinaseSeeker split luciferase assay:** 10 mM stock solutions of the compounds were serially diluted in DMSO to make assay stocks. Prior to initiating IC<sub>50</sub> determinations, the test compounds were evaluated for false positives against split-luciferase. Each test compound was screened in duplicate at 1 μM against STK17A and STK17B. Cfluc-kinase was translated along with Fos-Nfluc using a cell-free system (rabbit reticulocyte lysate) at 30 °C for 90 min. 24 μL aliquot of this lysate containing either 1 μL of DMSO (for no-inhibitor control) or compound solution in DMSO was incubated for 30 min at room temperature followed by 1 h in presence of a kinase specific probe. 80 μL of luciferin assay reagent was added to each solution and luminescence was immediately measured on a luminometer. The % Inhibition was calculated using the following equation: % Inhibition = [ALU (Control) – ALU (Sample)]/ALU (Control) x 100. For IC<sub>50</sub>

determinations, each compound was tested at 8 different concentrations. The % Inhibition was plotted against compound concentration and the IC<sub>50</sub> was determined for each compound using an 8-point curve.

*NanoBRET assays:* NanoBRET assays were performed as previously described.<sup>25</sup> For STK17B the C-terminal NanoLuc fusion (STK17B-NL) was encoded in pFN32K expression vector, including flexible Gly-Ser-Ser-Gly linkers between NanoLuc and STK17B. A 10 µg/mL solution of DNA in Opti-MEM without serum was made containing 9 µg/mL of Carrier DNA (Promega) and 1 µg/mL of STK17B-NL for a total volume of 1.05 mL. To this solution was then added 31.5 µL of FuGENE HD (Promega) to form a lipid:DNA complex. The solution was then mixed by inversion 8 times and incubated at room temperature for 20 min. The resulting transfection complex (1.082 mL) was then gently mixed with 21 mL of HEK-293 cells (ATCC) suspended at a density of 2 x 10<sup>5</sup> cells/mL in DMEM (Gibco) + 10% FBS (Corning). 100 µL of this solution was dispensed into 96-well tissue culture treated plates (Corning #3917) followed by incubation (37 °C / 5 % CO<sub>2</sub>) for 24 h. The media was removed and replaced with 85 µL of room temperature Opti-MEM without phenol red. NanoBRET Tracer K9 (Promega) was used at a final concentration of 0.66 µM. A total of 5 µL per well (20x working stock of NanoBRET Tracer K9 [13.2 µM] in Tracer Dilution Buffer (Promega N291B) was added to all wells, except the “no tracer” control wells. All test compounds were prepared initially as concentrated (10 mM) stock solutions in 100% DMSO (Sigma), then diluted in Opti-MEM media (99%) to prepare 1 % DMSO working stock solutions. A total of 10 µL per well of the 10-fold test compound stock solutions (final assay concentration 0.1 % DMSO) were added. For “no compound” and “no tracer” control wells, a total of 10 µL per well of Opti-MEM plus DMSO (9 µL Opti-MEM with 1 µL DMSO) was added, final concentration 1 % DMSO). 96-well plates containing cells with NanoBRET Tracer K9 and test compounds at eleven concentrations (100 µL total volume per well) were equilibrated (37 °C / 5 % CO<sub>2</sub>) for 2 h. The plates were cooled to room temperature for 15 min. To measure NanoBRET signal, NanoGlo substrate (Promega) at a ratio of 1:166 to Opti-MEM media in combination with extracellular NanoLuc Inhibitor (Promega) diluted 1:500 (10 µL [30 mM stock] per 5 mL Opti-MEM plus substrate) were combined to create a 3X stock solution. A total of 50 µL of the 3X substrate/extracellular NanoLuc inhibitor were added to each well. The plates were read within 10 min on a GloMax Discover luminometer (Promega, Madison, WI, USA) equipped with 450 nm BP filter (donor) and 600 nm LP filter (acceptor), using 0.3 s integration time utilizing the “NanoBRET 618” protocol. Raw milliBRET (mBRET) values were obtained by dividing the acceptor emission values (600 nm) by the donor emission values (450 nm) then multiplying by 1000. Averaged control values were used to represent complete inhibition (no tracer control: Opti-MEM + DMSO only) and no inhibition (tracer only control: no compound, Opti-MEM + DMSO + Tracer K9 only) and were plotted alongside the raw mBRET values. Biological replicates were normalized and fit using Sigmoidal, 4PL binding curve in Prism Software (version 8, GraphPad, La Jolla, CA, USA). The experiment was performed n = 3. Average IC<sub>50</sub> and standard error (SE) were calculated in Prism Software.

*Kinetic Solubility:* Assays were performed at Analiza, Inc. 50-fold dilutions of each DMSO stock solution were prepared in singleton by combining 6µL of DMSO stock with 294µL of the appropriate media in a Millipore solubility filter plate with 0.45µM polycarbonate filter membrane using Hamilton Starlet liquid handling. The final DMSO Concentration was 2.0% and maximum theoretical compound concentration was 200µM (assuming stock concentration of 10 mM). The filter plate was heat sealed for the duration of the 24-hour incubation period. Phosphate Buffered Saline solution 10X, PBS (Fisher Bioreagent part number BP399-500) 50mL was added to approximately 450mL HPLC grade H<sub>2</sub>O. The volume of the solution was then adjusted to 500mL for a total dilution factor of 1:10 and a final PBS concentration of 1X. The samples were place on a rotary shaker (200 RPM) at ambient temperature (22.4 – 24.0 °C) then vacuum filtered. All filtrates were injected into the nitrogen detector for quantification on Analiza’s Automated Discovery Workstation. The solubility was calculated as µg/mL and corrected for background nitrogen.

**Microsomal Stability:** Assays were performed at Analiza, Inc. 10mM DMSO stock solutions were diluted to 0.5 mM with DMSO and again to 0.1 mM with acetonitrile. The resulting solution contained 0.1 mM test article in 20% DMSO /80% acetonitrile. A reaction plate was prepared by adding 691.25  $\mu$ L, pre-warmed (37°C) microsomal solution (0.63 mg/mL protein in 100mM  $KPO_4$  with 1.3mM EDTA) to an empty well of a 96 well plate and maintained at 37 °C. The diluted 0.1 mM compound (8.75  $\mu$ L) was added to the microsomal solution in the reaction plate and mixed thoroughly by repeated pipetting. The resulting solutions were pre-incubated for 5 min at 37 °C before preparing the T = 0 plates. An aliquot (160  $\mu$ L) of each reaction solution was added to an empty well of a 96 well plate, as an exact replicate of the Reaction Plate. Cold (4°C) MeOH (400  $\mu$ L) was added to each well and mixed thoroughly by repeated pipetting. NADPH Regeneration solution (40  $\mu$ L) was added to each well and mixed thoroughly by repeated pipetting. For the T = 30-minute Incubation Plates (-NADPH), an aliquot (160 $\mu$ L) of each reaction solution was added to an empty well of a 96 well plate, as an exact replicate of the Reaction Plate. LC-MS grade  $H_2O$  (40  $\mu$ L) was added to each well and mixed thoroughly by repeated pipetting. The plate was sealed and incubated at 37 °C for the incubation period. After incubation, cold (4 °C) MeOH (400  $\mu$ L) was added to each well and mixed thoroughly by repeated pipetting. For the T= 30-minute Incubation Plate (+NADPH), NADPH (95 $\mu$ L) was added to the remaining solution (microsomes + test compound) in each well in the previously-prepared reaction plate to initiate the reaction. The plate was sealed and incubated at 37°C for the incubation period. An aliquot (100 $\mu$ L) was removed from each well at the desired time point and dispensed into a well of a 96-well plate. 200 $\mu$ L of cold (4 °C) MeOH was added to quench the reaction. All plates were sealed, vortex and centrifuged at 3000 RPM, 4 °C for 15 min, and the supernatants are transferred for analysis by LC-TOFMS. The supernatant (20  $\mu$ L) was injected onto an AQUASIL C18 column and eluted using a fast-generic gradient program. TOFMS Data was acquired using Agilent 6538 Ultra High Accuracy TOF MS in extended dynamic range (m/z 100-1000) using generic MS conditions in positive mode. Following data acquisition, exact mass extraction and peak integration was performed using MassHunter Software (Agilent Technologies). The stability of the compound is calculated as the percent remaining of the unchanged parent compound at each time point (T= 30 min) relative to the peak area at T=0 minute.

**Lipophilicity:** LogD at pH 7.0 was calculated using the ChemAxon web interface <https://disco.chemaxon.com/calculators/demo/plugins/logd/>

**Enzyme assays:** Assays were performed at Eurofins discovery services as previously described.<sup>49</sup> Compounds were provided as 10 mM stock solutions and screened in 10 point dose-response at the  $K_m$  of ATP using the full-length recombinant protein. For STK17B, the enzyme was incubated with 8 mM MOPS pH 7.0, 0.2 mM EDTA, 0.05% BSA, 10 mM sodium chloride, 250  $\mu$ M KKRPRRRYSNVF, 10 mM Magnesium acetate and [ $\gamma$ -<sup>33</sup>P-ATP]. The reaction was initiated by the addition of the Mg/ATP mix. After incubation for 2 h at room temperature, the reaction was stopped by the addition of phosphoric acid to a concentration of 0.5%. 10  $\mu$ l of the stopped reaction was spotted onto a P30 filtermat and washed four times for 4 min in 0.425% phosphoric acid and once in methanol prior to drying and scintillation counting.

**Molecular Dynamics (MD) Simulation. STK17B in apo form:** The cocrystal structure of human STK17B with **11s** (PDB ID: 6Y6H) was downloaded. All the hetero atoms including **11s** and water molecules were removed. PDB files corresponding to the P-loop (residues 37–46) with R41 in conformations A and B were generated. Approximately 1.25  $\mu$ S unbiased full atom MD simulation was performed using GROMACS 2018.1<sup>50</sup> starting from the two conformations. The hydrogen atoms were converted to virtual sites to remove the fastest vibrational freedom. The protein was parameterized with the amber99sb-ildn and then solvated with TIP3P water model in a dodecahedron box. In order to neutralize the charge on the protein, sodium and chloride ions were added to the system. Verlet cutoff was used to define neighbor list for nonbonded interactions.<sup>51</sup> Particle Mesh Ewald (PME) was used to calculate long-range interactions.



Energy minimization was performed with steepest-descent algorithm and then with conjugate descent with  $F_{\text{max}} < 500 \text{ kJmol}^{-1}\text{nm}^{-1}$ . The canonical ensemble was carried out by heating the system from 0 K to 310 K, using velocity rescaling for 100 ps.<sup>52</sup> The isothermal-isobaric ensemble ( $P = 1 \text{ bar}$ ,  $T = 310 \text{ K}$ ) was carried out using the Berendsen barostat for 100 ps.<sup>53</sup> The unrestrained MD productions were collected using a time step of 5 fs after the isothermal-isobaric ensemble. The trajectories were processed and analyzed using the built-in tools of Gromacs and then visualized with PyMOL 2.3.2.

*STK17B in inhibitor bound form:* RosettaLoop<sup>54</sup> was used to model the missing residues (187-295) in STK17B bound to **4** (PDB ID: 6Y6F). Unbiased full atom MD simulation was performed using GROMACS 2018.1.<sup>50</sup> **4** and **11s** were parameterized with GAFF (General AMBER Force Field)<sup>55</sup> using ACPYPE (AnteChamber PYthon Parser interfacE).<sup>56</sup> The protein was parameterized with the amber99sb-ildn and then solvated with TIP3P water model in a dodecahedron box. The charge was neutralized by adding sodium and chloride ions to the system. Verlet cutoff was used to define neighbor list for nonbonded interactions.<sup>51</sup> Protein parameterization and simulation protocols were identical to those used in the STK18B apo simulation described above. VMD<sup>57</sup> was used to calculate RMSD and H-bond frequency. Xmgrace was used to plot the data. Trajectory was visualized with PyMOL 2.3.2.

*Sequence alignment of STK17A and STK17B orthologs:* Kinase domains of STK17A and STK17B orthologs were identified using previously curated hierarchical eukaryotic Protein Kinase (ePK) profiles.<sup>58</sup> The sequences were then aligned with MAFFT version 7.450.<sup>59</sup> The alignment was then visualized using BOXSHADE version 3.2.1.

**Basicity calculation.**  $\text{pK}_a$  was obtained from density functional theory (DFT) calculations using the molecular electrostatic potential as the descriptor. All DFT calculations were performed with the Gaussian 16 package version A03<sup>60</sup> with tight self-consistent field convergence criterion and ultrafine integration grids. A full structure optimization was first carried out at the B3LYP/6-311+G(d,p) level of theory. After the structure optimization, single point calculations were performed to obtain the molecular electrostatic potential using the pop=chelpg keyword<sup>61</sup> for each of the nuclei followed by a full NBO analysis.<sup>62</sup>

## Acknowledgements

The SGC, a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative EUbOPEN (No 875510), Janssen, Merck KGaA Darmstadt Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome. Funding for this project was provided by National Institutes of Health (1R44TR001916-02) to Luceome Biotechnologies and the SGC-UNC. Additional funding for the SGC-UNC was provided by UNC Lineberger Comprehensive Cancer Center, PharmAlliance, and National Institutes of Health (1R01CA218442-01 and 1U24DK116204-01). S.K. is grateful for support by the German cancer network (DKTK) and the Frankfurt cancer center (FCI). Funding for N.K. from the National Institutes of Health (1U01CA239106-01) is acknowledged. The authors thank staff at Diamond Light Source, BESSY II and DESY for their assistance during data collection, and the UNC Department of Chemistry Mass Spectrometry Core Laboratory for their assistance with compound characterization. NanoBRET assays were aided by the provision of a CAMKK2-NLuc clone by Carol C. Preta and Priscila Zonzini (SGC-UNICAMP, Brazil). Other NanoBRET constructs and tracer K9 were kindly provided by Promega Corporation (Madison WI). The authors thank Alexander Tropsha (UNC Chapel Hill) for insights and discussion of computational models and electrostatics calculations.


## References

1. Taylor, S. S.; Radzio-Andzelm, E., Three protein kinase structures define a common motif. *Structure* **1994**, *2* (5), 345-55.
2. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S., The Protein Kinase Complement of the Human Genome. *Science* **2002**, *298* (5600), 1912-1934.
3. Shiloh, R.; Bialik, S.; Kimchi, A., The DAPK family: a structure-function analysis. *Apoptosis* **2014**, *19* (2), 286-97.
4. Farag, A. K.; Roh, E. J., Death-associated protein kinase (DAPK) family modulators: Current and future therapeutic outcomes. *Med Res Rev* **2019**, *39* (1), 349-385.
5. McGargill, M. A.; Wen, B. G.; Walsh, C. M.; Hedrick, S. M., A deficiency in Drak2 results in a T cell hypersensitivity and an unexpected resistance to autoimmunity. *Immunity* **2004**, *21* (6), 781-91.
6. McGargill, M. A.; Choy, C.; Wen, B. G.; Hedrick, S. M., Drak2 regulates the survival of activated T cells and is required for organ-specific autoimmune disease. *J Immunol* **2008**, *181* (11), 7593-605.
7. Ramos, S. J.; Hernandez, J. B.; Gatzka, M.; Walsh, C. M., Enhanced T cell apoptosis within Drak2-deficient mice promotes resistance to autoimmunity. *J Immunol* **2008**, *181* (11), 7606-16.
8. Boly, R.; Gras, T.; Lamkami, T.; Guissou, P.; Seretein, D.; Kiss, R.; Dubois, J., Quercetin inhibits a large panel of kinases implicated in cancer cell biology. *Int J Oncol* **2011**, *38* (3), 833-42.
9. Hsu, K. C.; Sung, T. Y.; Lin, C. T.; Chiu, Y. Y.; Hsu, J. T.; Hung, H. C.; Sun, C. M.; Barve, I.; Chen, W. L.; Huang, W. C.; Huang, C. T.; Chen, C. H.; Yang, J. M., Anchor-based classification and type-C inhibitors for tyrosine kinases. *Sci Rep* **2015**, *5*, 10938.
10. Library of Integrated Network-based Cellular Signatures: TKI-258 KINOMEScan - Dataset (ID:20168). <http://lincs.hms.harvard.edu/db/datasets/20168/results?proteins=200117&proteins=200118>.
11. Leonczak, P.; Gao, L. J.; Ramadori, A. T.; Lescrinier, E.; Rozenski, J.; De Jonghe, S.; Herdewijn, P., Synthesis and structure-activity relationship studies of 2-(1,3,4-oxadiazole-2(3H)-thione)-3-amino-5-arylthieno[2,3-b]pyridines as inhibitors of DRAK2. *ChemMedChem* **2014**, *9* (11), 2587-601.
12. Jung, M. E.; Byun, B. J.; Kim, H. M.; Lee, J. Y.; Park, J. H.; Lee, N.; Son, Y. H.; Choi, S. U.; Yang, K. M.; Kim, S. J.; Lee, K.; Kim, Y. C.; Choi, G., Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening. *Bioorg Med Chem Lett* **2016**, *26* (11), 2719-23.
13. Ali, I.; Park, S.; Jung, M. E.; Lee, N.; Bibi, M.; Chae, C. H.; Yang, K.-M.; Kim, S.-J.; Choi, G.; Lee, K., Identification of TRD-35 as Potent and Selective DRAK2 Inhibitor. *Bull. Korean Chem. Soc.* **2020**, *41* (5), 567-569.
14. Wang, S.; Xu, L.; Lu, Y. T.; Liu, Y. F.; Han, B.; Liu, T.; Tang, J.; Li, J.; Wu, J.; Li, J. Y.; Yu, L. F.; Yang, F., Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet beta-cells from apoptosis. *Eur J Med Chem* **2017**, *130*, 195-208.
15. Huang, D.; Zhou, T.; Lafleur, K.; Nevado, C.; Caflich, A., Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. *Bioinformatics* **2010**, *26* (2), 198-204.
16. Muller, S.; Chaikuad, A.; Gray, N. S.; Knapp, S., The ins and outs of selective kinase inhibitor development. *Nat Chem Biol* **2015**, *11* (11), 818-21.
17. Hari, S. B.; Perera, B. G.; Ranjitkar, P.; Seeliger, M. A.; Maly, D. J., Conformation-selective inhibitors reveal differences in the activation and phosphate-binding loops of the tyrosine kinases Abl and Src. *ACS Chem Biol* **2013**, *8* (12), 2734-43.
18. Guimaraes, C. R.; Rai, B. K.; Munchhof, M. J.; Liu, S.; Wang, J.; Bhattacharya, S. K.; Buckbinder, L., Understanding the impact of the P-loop conformation on kinase selectivity. *J Chem Inf Model* **2011**, *51* (6), 1199-204.
19. Drewry, D. H.; Wells, C. I.; Andrews, D. M.; Angell, R.; Al-Ali, H.; Axtman, A. D.; Capuzzi, S. J.; Elkins, J. M.; Etmayer, P.; Frederiksen, M.; Gileadi, O.; Gray, N.; Hooper, A.; Knapp, S.; Laufer, S.; Luecking, U.; Michaelides, M.; Muller, S.; Muratov, E.; Denny, R. A.; Saikatendu, K. S.; Treiber, D. K.; Zuercher,

- W. J.; Willson, T. M., Progress towards a public chemogenomic set for protein kinases and a call for contributions. *PLoS One* **2017**, *12* (8), e0181585.
20. Ni, Y.; Gopalsamy, A.; Cole, D.; Hu, Y.; Denny, R.; Ipek, M.; Liu, J.; Lee, J.; Hall, J. P.; Luong, M.; Telliez, J. B.; Lin, L. L., Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors. *Bioorg Med Chem Lett* **2011**, *21* (19), 5952-6.
  21. Drewry, D. H.; Wells, C. I.; Zuercher, W. J.; Willson, T. M., A Perspective on Extreme Open Science: Companies Sharing Compounds without Restriction. *SLAS Discov* **2019**, *24* (5), 505-514.
  22. Lieske, J.; Cerv, M.; Kreida, S.; Komadina, D.; Fischer, J.; Barthelmess, M.; Fischer, P.; Pakendorf, T.; Yefanov, O.; Mariani, V.; Seine, T.; Ross, B. H.; Crosas, E.; Lorbeer, O.; Burkhardt, A.; Lane, T. J.; Guenther, S.; Bergtholdt, J.; Schoen, S.; Tornroth-Horsefield, S.; Chapman, H. N.; Meents, A., On-chip crystallization for serial crystallography experiments and on-chip ligand-binding studies. *IUCr* **2019**, *6* (Pt 4), 714-728.
  23. Rydberg, P.; Gloriam, D. E.; Zaretski, J.; Breneman, C.; Olsen, L., SMARTCyp: A 2D Method for Prediction of Cytochrome P450-Mediated Drug Metabolism. *ACS Med Chem Lett* **2010**, *1* (3), 96-100.
  24. Jester, B. W.; Cox, K. J.; Gaj, A.; Shomin, C. D.; Porter, J. R.; Ghosh, I., A coiled-coil enabled split-luciferase three-hybrid system: applied toward profiling inhibitors of protein kinases. *J Am Chem Soc* **2010**, *132* (33), 11727-35.
  25. Vasta, J. D.; Corona, C. R.; Wilkinson, J.; Zimprich, C. A.; Hartnett, J. R.; Ingold, M. R.; Zimmerman, K.; Machleidt, T.; Kirkland, T. A.; Huwiler, K. G.; Ohana, R. F.; Slater, M.; Otto, P.; Cong, M.; Wells, C. I.; Berger, B. T.; Hanke, T.; Glas, C.; Ding, K.; Drewry, D. H.; Huber, K. V. M.; Willson, T. M.; Knapp, S.; Müller, S.; Meisenheimer, P. L.; Fan, F.; Wood, K. V.; Robers, M. B., Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement. *Cell Chem Biol* **2018**, *25* (2), 206-214.e11.
  26. Roskoski, R., Jr., Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. *Pharmacol Res* **2020**, *152*, 104609.
  27. Cao, X.; Rong, C.; Zhong, A.; Lu, T.; Liu, S., Molecular acidity: An accurate description with information-theoretic approach in density functional reactivity theory. *J Comput Chem* **2018**, *39* (2), 117-129.
  28. Liu, S.; Pedersen, L. G., Estimation of molecular acidity via electrostatic potential at the nucleus and valence natural atomic orbitals. *J Phys Chem A* **2009**, *113* (15), 3648-55.
  29. Klemm, L. H.; Jacquot, R. D., Basicities of thienopyridines. Potentiometric determination and use in effecting chemical separations. *Journal of Electroanalytical Chemistry and Interfacial Electrochemistry* **1973**, *45* (2), 181-186.
  30. Kenny, P. W., Hydrogen bonding, electrostatic potential, and molecular design. *J Chem Inf Model* **2009**, *49* (5), 1234-44.
  31. Knapp, S.; Arruda, P.; Blagg, J.; Burley, S.; Drewry, D. H.; Edwards, A.; Fabbro, D.; Gillespie, P.; Gray, N. S.; Kuster, B.; Lackey, K. E.; Mazzafera, P.; Tomkinson, N. C.; Willson, T. M.; Workman, P.; Zuercher, W. J., A public-private partnership to unlock the untargeted kinome. *Nat Chem Biol* **2013**, *9* (1), 3-6.
  32. Fedorov, O.; Muller, S.; Knapp, S., The (un)targeted cancer kinome. *Nat Chem Biol* **2010**, *6* (3), 166-169.
  33. Gatzka, M.; Newton, R. H.; Walsh, C. M., Altered thymic selection and increased autoimmunity caused by ectopic expression of DRAK2 during T cell development. *J Immunol* **2009**, *183* (1), 285-97.
  34. Miduturu, C. V.; Deng, X.; Kwiatkowski, N.; Yang, W.; Brault, L.; Filippakopoulos, P.; Chung, E.; Yang, Q.; Schwaller, J.; Knapp, S.; King, R. W.; Lee, J. D.; Herrgard, S.; Zarrinkar, P.; Gray, N. S., High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors. *Chem Biol* **2011**, *18* (7), 868-79.

35. Falke, H.; Chaikuad, A.; Becker, A.; Loaec, N.; Lozach, O.; Abu Jhaisha, S.; Becker, W.; Jones, P. G.; Preu, L.; Baumann, K.; Knapp, S.; Meijer, L.; Kunick, C., 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A. *J Med Chem* **2015**, *58* (7), 3131-43.
36. Parker, L. J.; Watanabe, H.; Tsuganezawa, K.; Tomabechi, Y.; Handa, N.; Shirouzu, M.; Yuki, H.; Honma, T.; Ogawa, N.; Nagano, T.; Yokoyama, S.; Tanaka, A., Flexibility of the P-loop of Pim-1 kinase: observation of a novel conformation induced by interaction with an inhibitor. *Acta Crystallogr Sect F Struct Biol Cryst Commun* **2012**, *68* (Pt 8), 860-6.
37. Xing, L.; Rai, B.; Lunney, E. A., Scaffold mining of kinase hinge binders in crystal structure database. *J Comput Aided Mol Des* **2014**, *28* (1), 13-23.
38. Xing, L.; Klug-Mcleod, J.; Rai, B.; Lunney, E. A., Kinase hinge binding scaffolds and their hydrogen bond patterns. *Bioorg Med Chem* **2015**, *23* (19), 6520-7.
39. Attia, M. H.; Elrazaz, E. Z.; El-Emam, S. Z.; Taher, A. T.; Abdel-Aziz, H. A.; Abouzid, K. A. M., Synthesis and in-vitro anti-proliferative evaluation of some pyrazolo[1,5-a]pyrimidines as novel larotrectinib analogs. *Bioorg Chem* **2020**, *94*, 103458.
40. Golub, A. G.; Bdzholá, V. G.; Briukhovetska, N. V.; Balanda, A. O.; Kukharenko, O. P.; Kotey, I. M.; Ostrynska, O. V.; Yarmoluk, S. M., Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. *Eur J Med Chem* **2011**, *46* (3), 870-6.
41. Arrowsmith, C. H.; Audia, J. E.; Austin, C.; Baell, J.; Bennett, J.; Blagg, J.; Bountra, C.; Brennan, P. E.; Brown, P. J.; Bunnage, M. E.; Buser-Doepner, C.; Campbell, R. M.; Carter, A. J.; Cohen, P.; Copeland, R. A.; Cravatt, B.; Dahlin, J. L.; Dhanak, D.; Edwards, A. M.; Frederiksen, M.; Frye, S. V.; Gray, N.; Grimshaw, C. E.; Hepworth, D.; Howe, T.; Huber, K. V.; Jin, J.; Knapp, S.; Kotz, J. D.; Kruger, R. G.; Lowe, D.; Mader, M. M.; Marsden, B.; Mueller-Fahrnow, A.; Muller, S.; O'Hagan, R. C.; Overington, J. P.; Owen, D. R.; Rosenberg, S. H.; Roth, B.; Ross, R.; Schapira, M.; Schreiber, S. L.; Shoichet, B.; Sundstrom, M.; Superti-Furga, G.; Taunton, J.; Toledo-Sherman, L.; Walpole, C.; Walters, M. A.; Willson, T. M.; Workman, P.; Young, R. N.; Zuercher, W. J., The promise and peril of chemical probes. *Nat Chem Biol* **2015**, *11* (8), 536-41.
42. O'Byrne, S. N.; Scott, J. W.; Pilotte, J. R.; Santiago, A. D. S.; Langendorf, C. G.; Oakhill, J. S.; Eduful, B. J.; Counago, R. M.; Wells, C. I.; Zuercher, W. J.; Willson, T. M.; Drewry, D. H., In Depth Analysis of Kinase Cross Screening Data to Identify CAMKK2 Inhibitory Scaffolds. *Molecules* **2020**, *25* (2), 325.
43. Powell, H. R.; Battye, T. G. G.; Kontogiannis, L.; Johnson, O.; Leslie, A. G. W., Integrating macromolecular X-ray diffraction data with the graphical user interface iMosflm. *Nat Protoc* **2017**, *12* (7), 1310-1325.
44. Potterton, L.; Agirre, J.; Ballard, C.; Cowtan, K.; Dodson, E.; Evans, P. R.; Jenkins, H. T.; Keegan, R.; Krissinel, E.; Stevenson, K.; Lebedev, A.; McNicholas, S. J.; Nicholls, R. A.; Noble, M.; Pannu, N. S.; Roth, C.; Sheldrick, G.; Skubak, P.; Turkenburg, J.; Uski, V.; von Delft, F.; Waterman, D.; Wilson, K.; Winn, M.; Wojdyr, M., CCP4i2: the new graphical user interface to the CCP4 program suite. *Acta Crystallogr D Struct Biol* **2018**, *74* (Pt 2), 68-84.
45. McCoy, A. J., Solving structures of protein complexes by molecular replacement with Phaser. *Acta Crystallogr D Biol Crystallogr* **2007**, *63* (Pt 1), 32-41.
46. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K., Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* **2010**, *66* (Pt 4), 486-501.
47. Murshudov, G. N.; Skubak, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A., REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallogr D Biol Crystallogr* **2011**, *67* (Pt 4), 355-67.
48. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P., Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol* **2011**, *29* (11), 1046-51.


49. Gao, Y.; Davies, S. P.; Augustin, M.; Woodward, A.; Patel, U. A.; Kovelman, R.; Harvey, K. J., A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. *Biochem J* **2013**, *451* (2), 313-28.
50. Abraham, M. J.; Murtola, T.; Schulz, R.; Pall, S.; Smith, J. C.; Hess, B.; Lindahl, E., GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. *SoftwareX* **2015**, *1-2*, 19-25.
51. Pall, S.; Hess, B., A flexible algorithm for calculating pair interactions on SIMD architectures. *Computer Physics Communications* **2013**, *184* (12), 2641-2650.
52. Bussi, G.; Donadio, D.; Parrinello, M., Canonical sampling through velocity rescaling. *J Chem Phys* **2007**, *126* (1), 014101.
53. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; DiNola, A.; Haak, J. R., Molecular dynamics with coupling to an external bath. *J. Chem. Phys.* **1984**, *81* (8), 3684-3690.
54. Wang, C.; Bradley, P.; Baker, D., Protein-protein docking with backbone flexibility. *J Mol Biol* **2007**, *373* (2), 503-19.
55. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A., Development and testing of a general amber force field. *J Comput Chem* **2004**, *25* (9), 1157-74.
56. Sousa da Silva, A. W.; Vranken, W. F., ACPYPE - AnteChamber PYthon Parser interfacE. *BMC Res Notes* **2012**, *5*, 367.
57. Humphrey, W.; Dalke, A.; Schulten, K., VMD: visual molecular dynamics. *J Mol Graph* **1996**, *14* (1), 33-8, 27-8.
58. McSkimming, D. I.; Dastgheib, S.; Baffi, T. R.; Byrne, D. P.; Ferries, S.; Scott, S. T.; Newton, A. C.; Evers, C. E.; Kochut, K. J.; Evers, P. A.; Kannan, N., KinView: a visual comparative sequence analysis tool for integrated kinome research. *Mol Biosyst* **2016**, *12* (12), 3651-3665.
59. Katoh, K.; Standley, D. M., MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* **2013**, *30* (4), 772-80.
60. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, J. L.; Williams-Young, D.; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Throssell, K.; J. A. Montgomery, J.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. *Gaussian 16*, Revision A.03; Gaussian, Inc.: Wallingford, CT, 2016.
61. Chirlian, L. E.; Francl, M. M., Atomic charges derived from electrostatic potentials – a detailed study. *J. Comp. Chem.* **1987**, *8*, 894-905.
62. Weinhold, F.; Carpenter, J. E., In *The Structure of Small Molecules and Ions*, Naaman, R.; Vager, Z., Eds. Plenum: 1988; pp 227-36.

**Table 1. Thieno[3,2-*d*]pyrimidines with STK17B activity**

Entry	Compound	X	R <sup>1</sup>	R <sup>2</sup>	DiscoverX <sup>a</sup>			
					<i>scan</i> MAX S <sub>10</sub> (1 μM)	STK17A K <sub>D</sub> (nM)	STK17B K <sub>D</sub> (nM)	Tpl2 <sup>b</sup> IC <sub>50</sub> (nM)
1	PFE-PKIS 43 ( <b>4</b> )	S	SCH <sub>3</sub>	H	0.005	230	3.8	3400
2	PFE-PKIS 14 ( <b>5</b> )	S	CONH <sub>2</sub>	H	0.020	270	11	1500
3	PFE-PKIS 9 ( <b>6</b> )	O	-NHN=C-		0.012	250	30	1000

<sup>a</sup> DiscoverX KINOMEscan. *scan*MAX, S<sub>10</sub>(1 μM) = number of kinases with 10 % or less of control activity remaining at 1 μM / number of wild type kinases tested (403), n = 1. K<sub>D</sub>, determined by dose response, n = 2. <sup>b</sup> Reported by Ni *et al* (reference 20).

**Table 2. Initial SAR**




Entry	Compound	Scaffold	X	R <sup>1</sup>	R <sup>2</sup>	KinaseSeeker <sup>a</sup>		NanoBRET <sup>b</sup>	
						STK17A (% I)	STK17B (% I)	STK17B IC <sub>50</sub> (nM)	STK17B IC <sub>50</sub> (nM)
1	<b>4</b>	<b>A</b>	S	OH	SCH <sub>3</sub>	15	90	20 ± 3.9	310 ± 40
2	<b>11a</b>	<b>A</b>	S	OH	Cl	3	90	39 ± 8.2	680 ± 190
3	<b>12</b>	<b>A</b>	S	NH <sub>2</sub>	SCH <sub>3</sub>	1	61	—	>10,000
4	<b>14</b>	<b>A</b>	O	OEt	Cl	4	36	—	>10,000
5	<b>15</b>	<b>A</b>	O	OH	Cl	0	36	—	>10,000
6	<b>16</b>	<b>A</b>	NH	OEt	SCH <sub>3</sub>	4	0	—	>10,000
7	<b>19a</b>	<b>B</b>	S	OH	SCH <sub>3</sub>	0	26	—	>10,000
8	<b>19b</b>	<b>B</b>	S	OH	OCH <sub>3</sub>	14	18	—	>10,000

<sup>a</sup> KinaseSeeker split luciferase binding assay. % I, inhibition compared to control (DMSO) at 1 μM, n = 2, data ± 10%. IC<sub>50</sub>, determined by dose response, n = 2 ± SD. — not determined. <sup>b</sup> Target engagement determined by NanoBRET assay in HEK293 cells, n = 3 ± SE.




**Table 3. SAR of 6-aryl substituents**



Entry	Compound	Scaffold	Ar	KinaseSeeker <sup>a</sup>		NanoBRET <sup>b</sup>	
				STK17A (% I)	STK17B (% I)	STK17B IC <sub>50</sub> (nM)	STK17B IC <sub>50</sub> (nM)
1	<b>11b</b>	<b>C</b>		12	94	49 ± 12	3,100 <sup>c</sup>
2	<b>11c</b>	<b>C</b>		30	90	110 ± 12	1,210 <sup>c</sup>
3	<b>11d</b>	<b>C</b>		0	90	49 ± 7.9	>10,000
4	<b>11e</b>	<b>C</b>		0	90	41 ± 6.9	380 ± 62
5	<b>11f</b>	<b>C</b>		8	96	28 ± 3.4	120 ± 6.0
6	<b>11g</b>	<b>C</b>		0	88	59 ± 8.0	660 <sup>c</sup>
7	<b>11h</b>	<b>C</b>		0	83	62 ± 9.0	530 ± 46
8	<b>11i</b>	<b>C</b>		0	91	92 ± 6.7	2,400 <sup>c</sup>
9	<b>11j</b>	<b>C</b>		0	81	110 ± 12	>10,000
10	<b>19c</b>	<b>D</b>		23	43	—	>10,000
11	<b>19d</b>	<b>D</b>		0	18	—	>10,000
12	<b>19e</b>	<b>D</b>		6	46	880 ± 120	>10,000
13	<b>19f</b>	<b>D</b>		0	3	—	>10,000

<sup>a</sup> KinaseSeeker split luciferase binding assay. % I, inhibition compared to control (DMSO) at 1 μM, n = 2, data ± 10%. IC<sub>50</sub>, determined by dose response, n = 2 ± SD. — not determined. <sup>b</sup> Target engagement determined by NanoBRET assay in HEK293 cells, n = 3 ± SE. <sup>c</sup> n = 1.


**Table 4. SAR of polar 6-aryl substituents**



Entry	Compound	Ar	KinaseSeeker <sup>a</sup>		NanoBRET <sup>b</sup>	
			STK17A (% I)	STK17B (% I)	STK17B IC <sub>50</sub> (nM)	STK17B IC <sub>50</sub> (nM)
1	<b>11k</b>		7	93	23 ± 2.4	>10,000
2	<b>11l</b>		24	94	35 ± 4.5	>10,000
3	<b>11m</b>		11	95	7 ± 0.72	>10,000
4	<b>11n</b>		21	96	13 ± 1.6	1,450
5	<b>11o</b>		20	92	83 ± 8.4	5,200
6	<b>11p</b>		37	98	14 ± 1.1	620
7	<b>11q</b>		9	93	37 ± 3.5	>10,000

<sup>a</sup> KinaseSeeker split luciferase binding assay. % I, inhibition compared to control (DMSO) at 1 μM, n = 2, data ± 10%. IC<sub>50</sub>, determined by dose response, n = 2 ± SD. <sup>b</sup> Target engagement determined by NanoBRET assay in HEK293 cells, n = 1.


**Table 5. SAR of lipophilic 6-substituents**



Entry	Compound	Ar	KinaseSeeker <sup>a</sup>		NanoBRET <sup>b</sup>	
			STK17A (% I)	STK17B (% I)	STK17B IC <sub>50</sub> (nM)	STK17B IC <sub>50</sub> (nM)
1	<b>11r</b>		13	91	63 ± 5.1	760 <sup>c</sup>
2	<b>11s</b>		0	93	43 ± 3.5	190 ± 61
3	<b>11t</b>		13	93	35 ± 3.4	3,700 <sup>c</sup>
4	<b>11u</b>		1	95	40 ± 5.7	2,200 <sup>c</sup>

<sup>a</sup> KinaseSeeker split luciferase binding assay. % I, inhibition compared to control (DMSO) at 1 μM, n = 2, data ± 10%. IC<sub>50</sub>, determined by dose response, n = 2 ± SD. <sup>b</sup> Target engagement determined by NanoBRET assay in HEK293 cells, n = 3 ± SD. <sup>c</sup> n = 1.


**Table 6. SAR of fluorine substituted 6-aryl substituents**



Entry	Compound	Ar	KinaseSeeker <sup>a</sup>		NanoBRET <sup>b</sup>	
			STK17A (% I)	STK17B (% I)	STK17B IC <sub>50</sub> (nM)	STK17B IC <sub>50</sub> (nM)
1	<b>11v</b>		8	94	49 ± 7.8	1,800 <sup>c</sup>
2	<b>11w</b>		22	90	60 ± 17	1,720 <sup>c</sup>
3	<b>11x</b>		1	83	74 ± 19	1,670 <sup>c</sup>
4	<b>11y</b>		0	93	27 ± 5.1	530 ± 450
5	<b>11z</b>		0	94	18 ± 2.6	4,000 ± 3,000
6	<b>11aa</b>		0	92	33 ± 5.2	520 <sup>c</sup>
7	<b>11ab</b>		13	75	280 ± 25	500 ± 100

<sup>a</sup> KinaseSeeker split luciferase binding assay. % I, inhibition compared to control (DMSO) at 1 μM, n = 2, data ± 10%. IC<sub>50</sub>, determined by dose response, n = 2 ± SD. <sup>b</sup> Target engagement determined by NanoBRET assay in HEK293 cells, n = 3 ± SD. <sup>c</sup> n = 1.

**Table 7. Microsomal stability and physiochemical properties**



Entry	Compound	Ar	Microsomal stability (%) <sup>b</sup>	Aq. solubility (μg/mL) <sup>b</sup>	cLogD <sup>c</sup>
1	<b>4</b>		0	42	1.27
2	<b>11u</b>		0	59	0.90
3	<b>11y</b>		18	52	1.28
4	<b>11c</b>		24	69	0.33
5	<b>11g</b>		35	23	1.95
6	<b>11f</b>		38	74	1.41
7	<b>11w</b>		45	51	0.77
8	<b>11r</b>		47	56	0.33
9	<b>11p</b>		63	61	0.61
10	<b>11s</b>		63	5	1.65
11	<b>11h</b>		66	55	1.49
12	<b>11o</b>		73	54	0.60
13	<b>11z</b>		88	49	0.47
14	<b>11aa</b>		88	57	1.49
15	<b>11x</b>		95	65	0.72

<sup>a</sup> % compound remaining in mouse liver microsomes at 30 min. <sup>b</sup> Kinetic solubility at pH 7.4.



<sup>c</sup> Calculated LogD at pH 7.0.

**Table 8. Kinase selectivity of chemical probe (11s)**

Kinase	KINOMEScan <sup>a</sup>		Enzyme <sup>b</sup>	NanoBRET <sup>c</sup>
	% I	K <sub>D</sub>	IC <sub>50</sub> (nM)	IC <sub>50</sub> (nM)
MET	100	>10,000	>10,000	—
NEK6	100	>10,000	>10,000	—
PIM2	100	1500	>10,000	—
WEE1	100	>10,000	>10,000	—
STK17B	99	5.6	34	190
CAMKK2	92	21	>10,000	2,400
AURKB	86	110	8900	>10,000
CAMKK1	86	49	5200	—
STK38L	71	>10,000	>10,000	>10,000
STK17A	27	440	4700	>10,000


<sup>a</sup> DiscoverX KINOMEScan. % I, scanMAX % inhibition of control at 1  $\mu$ M, n = 1. K<sub>D</sub>, determined by dose response, n = 2. <sup>b</sup> IC<sub>50</sub> for enzyme inhibition at K<sub>m</sub> ATP determined at Eurofins, n = 2. <sup>c</sup> Target engagement IC<sub>50</sub> determined by NanoBRET assay in HEK293 cells. — not determined.

**Table 9. STK17B potency and relative basicity of chemical probe (11s) and negative control (19g)**

	 SGC-STK17B-1 ( <b>11s</b> )	 SGC-STK17B-1N ( <b>19g</b> )
<b>STK17B:</b>		
Binding $K_D$ (nM) <sup>a</sup>	5.6	910
Enzyme $IC_{50}$ (nM) <sup>b</sup>	34	4,800
Cell $IC_{50}$ (nM) <sup>c</sup>	190	>10,000
<b>Basicity:</b>		
$pK_a$ (N1) <sup>d</sup>	2.8	0.1
$pK_a$ (N3) <sup>d</sup>	1.1	0.5


<sup>a</sup>  $K_D$ , determined by dose response at DiscoverX, n = 2. <sup>b</sup>  $IC_{50}$  for enzyme inhibition at  $K_m$  ATP determined at Eurofins, n = 2. <sup>c</sup> Target engagement  $IC_{50}$  determined by NanoBRET assay in HEK293 cells, n = 3. <sup>d</sup>  $pK_a$  was obtained from density functional theory (DFT) calculations using the molecular electrostatic potential as the descriptor.

### Scheme 1<sup>a</sup>




<sup>a</sup> Reagents and conditions: (a) (i) LDA 1.2 equiv, THF, -78 °C, 20 min, (ii) I<sub>2</sub> 1.2 equiv, -78 °C, 20 min, rt, 12 h, 68%; (b) (i) ethyl 2-mercaptoacetate 1.5–2.0 equiv, MeOH, 0 °C, (ii) Et<sub>3</sub>N 3–4 equiv, 0 °C to rt, 12 h, 65%; (c) (i) 1 M LiOH (aq) 2.0 equiv, THF:EtOH 1:1, 70 °C, 1 h, (ii) 1 M HCl (aq) until pH 2–3, 0 °C, 80%; (d) (i) ArB(OH)<sub>2</sub> 1.1 equiv., PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> 5 mol%, K<sub>2</sub>CO<sub>3</sub> 2.2 equiv., 1,4-dioxane:water 3:1, 95 °C, 3–12 h, (ii) 1 M HCl (aq) until pH 2–3, 0 °C 30–65%; (e) HATU 1.0 equiv, ammonia (aq) excess, *N,N*-diisopropylethylamine 2.2 equiv, DMF, rt, 12 h, 25%.

### Scheme 2<sup>a</sup>




<sup>a</sup> Reagents and conditions: (a) 4-Chlorophenylboronic acid 1.0 equiv or 4-(methylthio)phenylboronic acid 1.0 equiv, Pd(PPh<sub>3</sub>)<sub>4</sub> 5 mol%, NaHCO<sub>3</sub> 1.0 equiv, CsF 1.0 equiv, 1,4-dioxane:water 3:1, 95 °C, 3 h, 55%; (b) ethyl 2-hydroxyacetate 2.0 equiv, NaH 2.6 equiv. (60% dispersion in mineral oil), anhydrous DMF, 100 °C, 30 min microwave, 45%; or ethyl glycinate hydrochloride 2.5 equiv, TEA 10 equiv, EtOH, 90 °C, 18 h, 78%; (c) (i) LiOH 2.2 equiv, THF, 70 °C, 4h, (ii) 1 M HCl (aq) until pH 2–3, 0 °C, 82%.

### Scheme 3<sup>a</sup>




<sup>a</sup> Reagents and conditions: (a) (i) 2-mercaptoacetic acid 1.25 equiv, EtOH or CH<sub>3</sub>CN, 0 °C, (ii) TEA 2.5 equiv, 0 °C to rt, 12 h, (iii) 1 M HCl (aq) until pH 2–3, 0 °C, 75%; (b) (i) ArB(OH)<sub>2</sub> 1.0 equiv., Pd(PPh<sub>3</sub>)<sub>4</sub> 5 mol%, K<sub>2</sub>CO<sub>3</sub> 3–4 equiv, 1,4-dioxane:water 3:1, 95 °C, 3 h, (ii) 1 M HCl (aq) until pH 2–3, 0 °C 48–65%.







**Figure 1.** Chemical structures of STK17B inhibitors.




**Figure 2.** X-ray structure of the catalytic domain of STK17B. (A) STK17B/4 complex. STK17B protein backbone is shown in green. The side chains of R41, K62, and the backbone amide of A113 are highlighted. **4** is shown as sticks with atoms colored C pink, N blue, O red, and S yellow. (B) STK17B/4 complex. Alternate view showing the interaction of the carboxylic acid of **4** with R41 and K62. The unusual conformation of the P-loop is further stabilized by a salt bridge between R41 and E117. (C) STK17B/ADP complex (PDB 6QF4). STK17B protein backbone is shown in light blue. The side chains of R41, K62, E111, E117 and the backbone amide of A113 are highlighted. ADP is shown as sticks with atoms colored C pink, N blue, O red, and P orange.



**Figure 3.** X-ray structure of the catalytic domain of STK17B. (A) STK17B/**11s** complex. STK17B protein backbone is shown with the P-loop conformation A in green and the P-loop conformation B in light blue. The side chains of R41, K62, and the backbone amide of A113 are highlighted. **11s** is shown as sticks with atoms colored C pink, N blue, O red, and S yellow. (B) STK17B/**11s** complex conformation A showing the interaction of **11s** carboxylic acid with R41 and K62. Conformation A of the P-loop is further stabilized by a salt bridge between R41 and E117. (C) STK17B/**11s** complex conformation B showing the interaction of **11s** carboxylic acid with only K62 and A113. (D) STK17B/quercetin complex. STK17B protein backbone is shown in light blue. The side chains of R41, E80, D179 and the backbone amides of E111 and A113 are highlighted. Quercetin is shown as sticks with atoms colored C pink and O red. (E) STK17B/dovitinib complex. STK17B protein backbone is shown in light blue. The side chains of R41, K62 and the backbone amides of E111 and A113 are highlighted. Dovitinib is shown as sticks with atoms colored C pink, N blue, F pale blue and O red.



**Figure 4.** MD simulation of apo-STK17B. R41 and key residues forming interactions are shown as sticks and colored in magenta and salmon, respectively. (A) R41 starting in conformation A. After 1000 ns of the simulation, R41 flips to conformation B. (B) R41 starting in conformation B, where it remains throughout the simulation.



**Figure 5.** MD simulation of inhibitor bound STK17B. (A) RMSD plot of ligands (**4** or **11s**) during the course of simulation. GROMACS 2018.1 built-in tool was used to calculate RMSD of the ligand after least square fit using the C $\alpha$  atoms. (B) Total number of hydrogen bonds between the ligand and STK17B during the simulation. (C) Total number of hydrogen bonds between the ligand and R41 during the simulation.